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1. Summary 
Introduction: Schizophrenia (SCZ) and bipolar disorder (BPD) are complex genetic disorders, 
each with a prevalence of 1% in the population worldwide. The high frequency and the severity of 
symptoms place them among the top 20 global causes of disability. Moreover, very few effective 
drugs are available, as their etiology is largely unknown. Early investigations have revealed a 
strong genetic contribution, estimated around 80%, and a consistent overlap between SCZ and 
BPD. Two main models have been proposed for their genetic architecture: the common disease-
common variant and the common disease-rare variant. Several genome-wide association studies 
(GWASs) have demonstrated that common polymorphisms play indeed a role, but they can 
account only for half of the observed genetic variance in liability. Therefore, attention has turned 
towards the discovery of rare, high-penetrant risk variants. Recent studies have finally proven the 
validity of both models, but the works have revealed also how the identification of rare 
susceptibility factors could be trivial, given the high genetic heterogeneity of SCZ and BPD. 
Aim of the study: This works aims at identifying rare risk variants for SCZ and BPD. A unique 
population sample is investigated, as all the patients come from the same closed community, 
living in Chioggia, close to the Venetian lagoon. This sample is characterized by an increased 
prevalence of SCZ and BPD, and about 150 familial cases were available. Considering the high 
rate of endogamy, a more homogenous genetic background is hypothesized, together with an 
enrichment in rare susceptibility factors, making the sample particularly valuable for the detection 
of these type of variants. 
Methods and Results: First results excluded a major role for copy number variants (CNVs), the 
best candidate high-penetrant variants for the disorders to date. Subsequent strategies were then 
applied with the intent of tracking haplotypes shared between patients. Preliminary data on 
linkage analyses, however, had provided no significant results. Consequently, a novel approach 
was set up, to identify haplotypes identical by descent (IBD), considering the common ancestry. 
This latter analysis is free from segregation constrains, accounting also for the incomplete 
penetrance and the high genetic heterogeneity that characterize these complex disorders, and 
that likely had hampered linkage investigations. IBD analysis was carried out with Relate software 
and output data were processes with specifically developed PERL scripts. 
Since IBD analysis was completely designed in this work, family information was initially used to 
verify the robustness of data. Indeed, genetic similarities estimated from IBD regions accurately 
reflected the biological relationships between pairs of individuals. Additionally, these estimates 
revealed a substantial relatedness between unrelated subjects, thus the population sample had 
some features of a population isolate. To get further insights into the connections among families, 
a cluster analysis was performed. Surprisingly, the outcome highlighted the presence of two main 
population subgroups, corresponding to the local origins of individuals (p=2.12 e-8). Samples 
were in fact collected from two closed areas, named Chioggia and Sottomarina. The studied 
population could be thus considered as composed by two extended families. 
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Once the reliability of IBD data had been established, IBD mapping was sought as a strategy to 
track susceptibility loci for SCZ and BPD. An in-house pipeline was thus developed to obtain a 
genome-wide map of shared haplotypes among all the subjects. Interestingly, some of the 
haplotypes were specific for a phenotype (SCZ or BPD) or an origin (Chioggia or Sottomarina); 
however, a consistent number of loci were common to the two population clusters, indicating a 
certain level of admixture. IBD map identified haplotypes shared across multiple families and, 
remarkably, some combinations of loci co-segregating in different families. This last observation 
was considered particularly relevant as it could indicate possible interplays of genetic factors 
consistently contributing to risk. 
From the total IBD map (IBDtot), a subset of haplotypes were selected (IBDsel), because possibly 
with a greater impact on the disorders, as they were shared by at least half of the patients of three 
or more families. 
For an in depth investigation of IBD haplotypes, 17 affected subjects were chosen for whole-
exome sequencing. Next-generation sequencing was carried out with Ion Torrent™ platform, 
while annotation and filtering were obtained by integrating IonReporter™ software and expressly 
created algorithms. 6,621 rare and novel variants were then mapped into IBDtot haplotypes; of 
these, 8.4% were located in IBDsel haplotypes. Interestingly, all these categories of variants were 
particularly affecting genes involved in axon guidance and synaptic transmission processes. More 
in details, variants were concerning definite nodes of neurite outgrowth and glutamatergic 
synapse functions, principally postsynaptic cascades activated by NMDA receptors. 
Using IBD map, sharing and segregation of variants could be inferred for the non-sequenced 
individuals, thus allowing the investigation of the entire population sample. A family-based 
analysis showed a recurrence of rare or novel alleles affecting axon guidance and synaptic 
transmission in each pedigree. This scenario is coherent with a polygenic contribution to the 
disorders. Sharing analysis identified variants segregating across different pedigrees, overall 
revealing a puzzle of alleles, each with a proper sharing pattern, compatible with a certain genetic 
heterogeneity. Among the strongest candidate genes with synaptic functions are GRM7 and 
GRM8, two metabotropic glutamate receptors, presenting two variants co-segregating with SCZ in 
the same family, and CACNA1E and DLG4, with variants shared across multiple pedigrees. 
Similarly, the NCAM1 and NCAN genes, whose products directly interact in neurite formation, 
were carrying variants in all the patients within the same family. 
Under the hypothesis of load of variants affecting the same biological process, it’s possible that 
the risk would be substantially increased by specific combinations of a few functionally related 
alleles. Coherently, variants on different chromosomes were found co-segregating across multiple 
pedigrees. For example, a combination of two variants in the ARHGAP32 and CDH13 genes was 
detected in 5 patients of two families. Both these genes are involved in modulating actin 
cytoskeleton remodelling, the first in NMDA receptor mediated cascades, the latter in response to 
neuronal adhesion processes. They are thus fundamental in neuronal projection formation and 
development. Their co-occurrence may pinpoint possible sites of vulnerability, that, when 
simultaneously affected, confer a high susceptibility for SCZ/BPD.  
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Discussion and conclusions: In this work a novel approach for the investigation of the genetic 
architecture of SCZ and BPD was presented, exploiting IBD mapping and WES in a family-based 
population sample. The approach offered several advantages, such as the possibility to efficiently 
prioritize variants and to investigate the entire population from a subset of individuals. The IBD 
map, then, represents a flexible tool to address specific questions relative to candidate risk 
factors, thus allowing the testing of specific hypothesis, such as the existence of haplotype 
combinations. 
Thanks to the integration of IBD and WES, some insights on SCZ/BPD etiology were obtained. 
More in details, specific processes related to neurosystem functions and development were 
implicated and some candidate variants were provided, therefore substantiating the role of rare 
variation in susceptibility. Considering the unique characteristics of the studied population, it’s 
difficult to predict whether the same alleles could be detected in independent samples. Despite, in 
the light also of the general convergence of all types of genetic studies, the results could suggest 
possible genes or nodes of pathways that, when affected, increase vulnerability to these 
psychiatric disorders. Further replications in other studies would thus support their involvement, 
finally suggesting new therapeutic targets for these common disorders that cause such a high 
burden for the society. 
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2. Riassunto 
Introduzione: la schizofrenia (SCZ) e il distrubo bipolare (BPD) sono malattie genetiche 
complesse, ciascuna con una prevalenza dell’1% nella popolazione mondiale. L’alta frequenza e 
la severità dei sintomi le rendono due delle prime 20 cause globali di disabilità. Inoltre, i farmaci 
disponibili sono pochi e solo parzialmente efficaci, conseguenza del fatto che l’eziologia di questi 
disordini è ancora largamente sconosciuta. Le prime evidenze hanno dimostrato una forte 
componente genetica, stimata intorno all’80%, e una consistente sovrapposizione tra SCZ e BPD. 
Due principali modelli sono stati proposti per descriverne l’architettura genetica, il primo definito 
‘malattia comune-varianti comuni’ e il secondo ‘malattia comune-varianti rare’. Numerosi studi di 
associazione sull’intero genoma (GWAS, genome-wide association study), hanno dimostrato 
l’effettivo coinvolgimento di polimorfismi comuni, tuttavia questi possono rendere conto solo di 
metà della varianza genetica stimata per i disordini. L’attenzione si è dunque spostata verso la 
ricerca di varianti rare. Recenti lavori hanno infine confermato la validità di entrambi i modelli 
genetici, ma hanno anche rivelato come l’identificazione di fattori rari di suscettibilità possa essere 
ardua, data l’estrema eterogeneità che caratterizza la schizofrenia e il disturbo bipolare. 
Scopo della ricerca: Questo lavoro ha come obiettivo l’identificazione di varianti rare che possano 
conferire rischio per SCZ e BPD. A questo proposito, viene investigato un particolare campione di 
popolazione, che si contraddistingue per il fatto che tutti i pazienti provengono da una comunità 
chiusa, residente a Chioggia, una città della laguna veneziana. Il campione è caratterizzato da 
un’elevata prevalenza di SCZ e BPD e circa 150 casi familiari erano disponibili per lo studio. 
Considerando l’alto tasso di endogamia, l’ipotesi iniziale è quella di una maggiore omogeneità 
genetica, e in particolare un arricchimento di fattori rari di suscettibilità, che rendono questo 
campione di estremo valore per l’identificazione di questo tipo di varianti. 
Metodi e risultati: i primi risultati ottenuti escludono un ruolo maggiore delle CNV (copy number 
variant), ritenute attualmente tra le migliori candidate per essere varianti rare di rischio per SCZ e 
BPD. Le strategie successive sono state quindi volte ad identificare aplotipi condivisi dai pazienti. 
Dati preliminari provenienti da analisi di linkage, tuttavia, non avevano fornito alcun segnale 
significativo. Di conseguenza, si è proceduto con la messa a punto di un approccio innovativo, 
per l’individuazione di aplotipi identici per discendenza (IBD, identical by descent), tenendo conto 
della comune origine dei pazienti. Quest’ultima analisi risulta svincolata da limiti imposti da metodi 
basati sulla segregazione ed è in grado di contemplare anche la penetranza incompleta e l’alta 
eterogeneità genetica che caratterizzano queste malattie complesse e che sono la causa dello 
scarso successo degli studi di linkare. L’analisi IBD è stata realizzata mediante il software Relate 
e l’output del programma è stato processato mediante script in linguaggio PERL, appositamente 
sviluppati. 
Essendo l’analisi IBD completamente progettata in questo lavoro, le relazioni familiari sono state 
inizialmente utilizzate per verificare l’affidabilità dei risultati. La similarità genetica, stimata a 
partire dalle regioni IBD identificate, ricalcava accuratamente i legami biologici esistenti tra coppie 
di individui. In aggiunta, queste stime hanno rivelato un elevato grado di similarità tra soggetti non 
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imparentati, suggerendo che il campione analizzato avesse in effetti alcune caratteristiche di una 
popolazione isolata. Per ottenere ulteriori informazioni relative alle connessioni esistenti tra le 
famiglie, è stata eseguita un’analisi di cluster. Sorprendentemente, i risultati hanno evidenziato la 
presenza di due principali sottogruppi di popolazione, corrispondenti all’origine locale degli 
individui. (p=2.12e-8). I campioni erano stati infatti raccolti in due regioni attigue, Chioggia e 
Sottomarina. La popolazione studiata può essere dunque considerata come composta di due 
‘super-familglie’. 
Stabilita l’affidabilità dei dati IBD, la mappatura IBD è stata impiegata con l’obiettivo di tracciare 
loci di suscettibilità per SCZ e BPD. Una specifica procedura bioinformatica è stata quindi 
sviluppata per ottenere una mappa genomica degli aplotipi condivisi dai soggetti. È interessante 
notare come alcuni degli aplotipi fossero specifici per un fenotipo (SCZ o BPD) o un’origine 
(Chioggia o Sottomarina); tuttavia, un consistente numero di loci era comune ai due cluster  di 
popolazione, indicando un certo livello di mescolanza. Attraverso la mappa IBD, è stato possibile 
identificare aplotipi condivisi tra le famiglie e, soprattutto, alcune combinazioni di loci che co-
segregavano in famiglie distinte. Quest’ultima osservazione è stata ritenuta particolarmente 
rilevante perché poteva indicare possibili interazioni di fattoti genetici che contribuiscono in modo 
sostanziale al rischio. 
A partire dalla mappa totale IBD (IBDtot), un sottoinsieme di aplotipi è stato selezionato (IBDsel), in 
quanto possibilmente con un impatto maggiore nei disordini, perché condivisi da almeno metà dei 
pazienti di tre o più famiglie.  
Per uno studio più approfondito degli aplotipi IBD, gli esomi di 17 soggetti affetti sono stati 
sequenziati. Il sequenziamento è stato eseguito mediante piattaforma IonTorrent™, mentre 
l’annotazione e il filtraggio delle varianti sono stati ottenuti tramite l’integrazione del software 
IonReporter™ con algoritmi espressamente creati. 6,621 varianti rare o nuove sono state 
mappate negli aplotipi IBDtot; di queste, l’8.4% era localizzato in aplotipi IBDsel.Da un punto di 
vista funzionale, queste varianti interessavano particolarmente geni coinvolti nei processi di axon 
guidance (formazione di proiezioni neuronali) e synaptic transmission (trasmissione sinaptica). 
Più nel dettaglio, le varianti cadevano in precisi nodi dei processi di ‘neurite outgrowth’ e funzioni 
relative alla sinapsi glutamatergica, principalmente in cascate di segnale attivate dai recettori 
NMDA: 
Utilizzando la mappa iBD, è stato possibile inferire la condivisione e la segregazione delle varianti 
anche in individui non sequenziati, permettendo così l’analisi dell’intero campione. Un’analisi a 
livello famigliare ha dimostrato una ricorrenza di varianti nei processi di axon guidance e synaptic 
transmission in ogni pedigree. Questo scenario è coerente con una natura poligenica dei 
disordini. L’esame della condivisione di tali varianti ha rivelato nel complesso un puzzle di alleli, 
ciascuno con un proprio schema di condivisione, compatibile con un certo livello di eterogeneità 
genetica. Tra i geni candidati con funzioni sinaptiche si ritrovano GRM7 e GRM8, due recettori 
metabotropici del glutammato, che presentano due varianti che co-segregano con la SCZ nella 
stessa famiglia, e CACNA1E e DLG4, con varianti condivise attraverso multiple famiglie. 
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Analogamente, i geni NCAM1 e NCAN, i cui prodotti interagiscono direttamente nel processo di 
formazione di proiezioni neuronali, erano colpiti da varianti in tutti gli affetti di una stessa famiglia.  
Sulla base dell’ipotesi di un carico di varianti che interessano lo stesso processo biologico, è 
possibile che il rischio possa essere sostanzialmente incrementato da specifiche combinazioni di 
alcuni alleli correlati funzionalmente. Coerentemente, varianti su cromosomi differenti co-
segregavano in multipli pedigree. Per esempio, una combinazione di due varianti nei geni 
ARHGAP32 e CDH13, è stata rilevata in 5 pazienti di due famglie. Entrambi questi geni sono 
coinvolti nel rimodellamento del citoscheletro di actina, il primo in cascate mediate da recettori 
NMDA, il secondo in risposta a processi di adesione neuronale. Sono quindi fondamentali per la 
formazione di proiezioni e nello sviluppo neuronale. La loro co-occorrenza potrebbe denotare 
possibili siti di vulnerabilità, che, quando simultaneamente colpiti, conferiscono un’alta 
suscettibilità per SCZ/BPD. 
Discussione e conclusioni: In questo lavoro, è stato presentato un nuovo approccio per 
l’investigazione dell’architettura genetica di SCZ e BPD, che sfrutta la combinazione di una 
mappa genomica IBD con il sequenziamento dell’intero esoma in un campione di popolazione 
composto da numerose famiglie. L’approccio ha offerto numerosi vantaggi, come la possibilità di 
prioritizzare in modo efficiente le varianti e di analizzare un intero campione di popolazione a 
partire da un piccolo gruppo di soggetti sequenziati. La mappa IBD, poi, rappresenta uno 
strumento flessibile per testare specifiche ipotesi relative a fattori di rischio candidati, come 
l’esistenza di combinazioni di aplotipi. 
Grazie all’integrazione di IBD e sequnenziamento dell’esoma, alcune informazioni sull’eziologia di 
SCZ e BPD sono state ottenute. Nello specifico, alcuni processi correlati a sviluppo e funzionalità 
del sistema nervoso sono stati implicati e alcune varianti candidate sono state evidenziate, 
supportando quindi il ruolo di varianti rare nella suscettibilità alle due malattie. Considerando le 
caratteristiche uniche della popolazione investigata, è difficile predire se gli stessi alleli possano 
essere rilevati in altri campioni indipendenti. Tuttavia, alla luce anche della generale convergenza 
degli studi genetici, questi risultati potrebbero suggerire possibili geni o nodi di processi che, 
quando mutati, possono incrementare la vulnerabilità a questi disordini psichiatrici. Ulteriori 
replicazioni sarebbero quindi utili nel confermarne il coinvolgimento, finalmente suggerendo nuovi 
bersagli terapeutici per queste malattie comuni che rappresentano un tale carico per la società. 
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1. Introduction 
 
1.1 Preface 
Schizophrenia and bipolar disorder: an overview on the study of psychiatric illnesses 
Mental health constitutes an actual issue in modern society: according to the World Health 
Organization (WHO) psychiatric disorders altogether represent the leading cause of disability 
worldwide (Department of Health Statistics and Information Systems WHO, Geneva, 2013). 
Schizophrenia (SCZ) and bipolar disorder (BPD) contribute significantly to the estimates, as they 
are individually placed in the top 20 positions of such a rank of disability causes. This strong 
impact on global health is ascribable both to the high frequency and the extreme severity of SCZ 
and BPD. The lifetime prevalence for each disorder is about 1% in the general population 
(American Psychiatric Association, 2013), with very small differences across countries and ethnic 
groups. Affected individuals have difficulties in basic personal and social tasks, including self 
caring and keeping a regular job. In addition, SCZ and BPD are mostly enduring illnesses, so that 
lifelong assistance is required, creating a consistent burden not only for patients and their 
families, but also for the society as a whole. SCZ in particular is considered one of the costliest 
diseases both in terms of human and financial resources (van Os & Kapur, 2009). 
Psychosis and mood alterations have been reported as early as ancient Greece age (Möller, 
2003), but only with the work of the German psychiatrist Emil Kraepelin, at the beginning of the 
20th century, have SCZ and BPD been recognized and classified as proper diseases (Kraepelin, 
1899). In a series of books published between 1893 and 1899, Kraepelin investigated mental 
conditions with the same criteria used for physical ones, identifying specific symptoms and 
courses. He further distinguished two main groups of insanities: Dementia Praecox and manic-
depressive illness. The term “Dementia Praecox” was used to describe a psychotic disease 
characterized by rapid cognitive disintegration, that, unlike senile dementia, occurred early in life. 
Conversely, manic-depressive disorder arose with repeated mood shifts, but without any cognitive 
involvement. These two categories broadly correspond to the modern SCZ and BPD definitions. 
Dementia Praecox was later renamed as schizophrenia (literally “split mind”) by Eugen Bleuer 
(Bleuer, 1908), who hypothesized at the basis of the disorder a detachment of cognition from 
emotions, behavior and volition. The term “bipolar disorder” was instead introduced in 1959 by 
Karl Kleist and Karl Leonhard to highlight the distinction from major depressive disorder, also 
called unipolar disorder (Angst & Marneros, 2001) 
The clear separation between an intellectual functioning disorder (SCZ) and a mood one (BPD) 
has marked a milestone in clinical practice and is largely known today as the “kraepelinian 
dichotomy”. Although still widely used for diagnostic purposes, this assumption has been recently 
challenged by growing evidence of an overlap between the two disorders. Whether the 
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“kraepelinian dichotomy” should be revised is currently a highly debated topic among psychiatrist 
(Craddock & Owen, 2010; Tesli et al., 2014). 
The conceptual definition of SCZ and BPD in early 1900 propelled the examination of their 
epidemiology in the worldwide population. It became immediately evident that the disorders 
aggregate in families, suggesting a genetic contribution in liability. This observation has been 
repeatedly confirmed by a line of studies, initiated by Franz Kallmann around 1930, on families, 
twins and adopted children. All these works have demonstrated that the genetic influence on SCZ 
and BPD is in fact substantial (Smoller & Finn, 2003; Patrick F Sullivan, Kendler, & Neale, 2003) 
and have converged also on a common etiology for the two disorders (Lichtenstein et al., 2009). 
In the light of these remarkable data, the genetics of SCZ and BPD has been extensively 
investigated. However, the genetic architecture has proven to be complex and extremely 
heterogeneous, with hundreds of genes possibly involved in the pathogenesis of both disorders 
(Harrison, 2015). Nevertheless, the understanding of the mechanisms underlying these 
psychiatric conditions is still of extreme importance for diagnosis and, especially, for treatment, 
given the unfavourable prognosis (American Psychiatric Association, 2013). The number of 
available drugs is indeed limited, with only partial effectiveness and strong side effects (Werner & 
Coveñas, 2015). For example, more than 50% of schizophrenic patients show some degree of 
resistance to antipsychotics (Falkai et al., 2015); in contrast, mood stabilizers can in general 
counteract manic symptoms, but are less efficient against the depressive state (Frye et al., 2014). 
Therefore, the identification of involved genes could help uncover new potential and possibly 
more specific therapeutic targets. In a long term perspective, the determination of the genetic 
profile would allow to predict the risk for an individual to develop a disease and for affected 
subjects to get personalized therapies (Purcell et al., 2009). 
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1.2 Clinical aspects of schizophrenia and bipolar disorder 
 
1.1.1 Schizophrenia 
Diagnosis of psychiatric disorders is generally defined following international guidelines. One of 
the most used reference text on this subject is the Diagnostic and Statistical Manual of mental 
disorder, published in its fifth edition (DSM-V, American Psychiatric Association, 2013). 
SCZ is a devastating mental disorder that affects cognition, behaviour and emotions. According to 
DSM-V, it is characterized by five main symptom domains. The first four domains are generally 
known as positive symptoms and include delusions, hallucinations, disorganized thinking and 
grossly disorganized or abnormal behaviour. Delusions are fixed beliefs that are held with 
certainty even in light of conflicting evidence; the most common delusions are persecutory, when 
patients are convinced they’re going to be harmed by an individual or an organization. 
Hallucinations are defined as perception-like experiences that occur without an external stimulus; 
they can involve any of the five senses, but almost all the schizophrenic subjects undergo 
auditory hallucinations and declare to hear voices in their heads clearly distinguishable from their 
thoughts. Disorganized thinking manifests itself with disorganized speech, revealed by the 
unjustified switch from one topic to another, or even incomprehensible talking. Finally, 
disorganized or abnormal behaviour may range from childlike “silliness” to extreme agitation; 
catatonia, a marked decrease in reactivity to the environment, is also classified among this last 
category.  
The fifth symptom domain consists of negative symptoms, that affect specifically the emotional 
and social sphere. Typical negative symptoms are a diminished emotional expression and 
avolition, a decrease in the motivation to perform self-directed actions (e.g. going to work or other 
general routine activities). Social withdrawal and anhedonia, the inability to feel pleasure from 
positive stimuli, are common as well. 
SCZ usually emerges with the first psychotic episode, identified by the persistent presence of at 
least one positive symptom. The onset of the disorder is in late adolescence to early adulthood, 
with a peak age in the mid-20s; childhood and late adulthood cases are also described, but are 
extremely rare. The psychotic episode is frequently preceded by a prodromal phase and followed 
by a residual one. Both these phases are characterized by mild positive symptoms and, mostly, 
negative ones. Another important feature that appears evident in non-psychotic periods is 
cognitive impairment, particularly in attention and memory functions, as originally observed by 
Kraepelin himself (Falkai et al., 2015). Although not considered as an inclusion criterion in DSM-
V, cognitive deficits are present in the majority of patients and are often the first sign of the 
disorder; for example, children who later develop SCZ have subtle intellectual and motor delays 
(van Os & Kapur, 2009).  
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The outcome of SCZ is generally unfavorable. Life expectancy is reduced of about 12-15 years, 
not only because of suicides, that affect 5-6% of patients, but also due to the poor self-care (e.g. 
poor diet, little exercise, substance abuse) and the lifelong use of drugs (van Os & Kapur, 2009), 
that expose individuals with SCZ to metabolic side effects (e.g. diabetes or cardiovascular 
diseases). Furthermore, only a small fraction of patients report a full recovery. Despite 
antipsychotic treatments, about a third of affected individuals experience relapses after the first 
psychotic episode (van Os & Kapur, 2009). Even when drugs are effective against positive 
symptoms, the residual phase frequently turns into a chronic disorder, because currently available 
drugs are unable to counteract negative symptoms. Moreover, cognitive alterations become a 
stable cognitive impairment and a progressive intellectual deterioration occurs. Thus, negative 
and cognitive symptoms are those mainly contributing to disability, so that patients require 
constant assistance in everyday life, making SCZ one of the most severe mental disorders 
worldwide. 
 
1.1.2 Bipolar disorder 
BPD is an affective disorder characterized by repeated shifts in mood, that influence thinking and 
behavior. Two main types of BPD are distinguished, namely type I and II (American Psychiatric 
Association, 2013). 
The typical sign of BPD I is mania. During a manic episode, mood is abnormally and constantly 
elevated, expansive or irritable. Patients experience an increased energy and a decrease need 
for sleep, a pressure of keep talking, but also distractibility and agitation, as well as an attraction 
for high-risk, dangerous activities (reduced risk perception). Besides, a rapid alternation between 
euphoria, dysphoria and irritability can be seen. All these disturbances strongly affect social and 
occupational life, and in some cases hospitalization is required. The manic episode by itself is 
sufficient for the diagnosis of BPD I, but more than 90% of cases have recurrent mood episodes. 
The typical manifestation is a cyclical change of mood from manic, hypomanic and/or depressive 
states, with variable intervals of normal mood. Hypomania denotes a less severe mania, where 
symptoms are similar but not enough to compromise everyday life. Depression is instead a 
mixture of feelings encompassing sadness, emptiness and hopelessness, combined with a 
markedly reduced interest in any activity, insomnia or hypersomnia, loss of energy and recurrent 
thought of death that persist for several days. 
In BPD II, proper manic episodes are absent and the predominant feature is major depression, in 
combination with at least one episode of hypomania. Although hypomanic symptoms are less 
serious than manic ones, BPD II can’t be considered a milder form of the disorder, as patients 
suffer from more enduring and disabling depressive episodes over time. In addition, the risk of 
relapses is higher than in BPD I. 
The onset of BPD is generally in the late teens, but first manic, hypomanic or depressive 
symptoms have been described at any age. Patients usually benefit from mood stabilizer drugs, 
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although at least 15-30% of them do not completely recover from mood episodes and show some 
degree of dysfunction even in normal mood state (Frye et al., 2014). As previously described, 
relapses are frequent and BPD becomes a lifelong, chronic disease. Similarly to SCZ, BPD is 
thus a disabling condition, that compromises personal, social and occupational life. Functional 
consequences contribute to the exacerbation of depression; as a proof, about one-third of cases 
attempt suicide (American Psychiatric Association, 2013). 
 
1.1.3 The clinical overlap of schizophrenia and bipolar disorder  
In the current diagnostic system, SCZ and BPD are considered distinct nosological entities, 
following the “kraepelinian dichotomy” (American Psychiatric Association, 2013). But in clinical 
practice, medical cases are particularly heterogeneous and symptoms are not exclusive of a 
disorder, transcending diagnostic boundaries. More than 50% of bipolar subjects, in fact, 
experience a psychotic episode in their lifetime; similarly, mood dysregulation is not rare in 
schizophrenic individuals and depression is a main feature of the characteristic negative 
symptoms, that become predominant in later stages (Lin & Mitchell, 2008). Also cognitive deficits, 
initially described as typical of SCZ, are observed in BPD, although in a less ubiquitous and 
profound extent (Simonsen et al., 2011). Moreover, both schizophrenic and bipolar cases are 
responsive to the same medications, such as antipsychotic drugs. As a result of this, it’s not 
uncommon that a patient receives multiple, contrasting diagnoses in the course of his life (Song et 
al., 2015). Further, a third disorder has been defined, the schizoaffective disorder (SZA), with the 
intent of grouping the variety of subjects with consistent signs of both SCZ and BPD; whether 
SZA represent a distinct entity is still controversial (American Psychiatric Association, 2013). In 
this light, the validity of the “kraepelinian dichotomy” has been strongly questioned, as the strict 
diagnostic categorization could be trivial and too simplistic to completely describe all the patient 
manifestations (Cardno & Owen, 2014). In contrast, a psychiatric continuum model has been 
proposed (Craddock & Owen, 2010; Möller, 2003), where SCZ and BPD symptoms are 
considered as part of a spectrum, ranging from psychosis to mania and depression. Even if such 
a hypothesis could more realistically represent the heterogeneity of symptoms found in patients, 
its application in clinical practice is not yet feasible. Nosological categories are indeed still 
acknowledged as the best instrument to address course and treatments. Neurobiological 
understanding of the disorders is actually too limited to reach a more refined diagnosis and at 
present deeper insights into mechanisms underlying etiology are therefore urgently required (Tesli 
et al., 2014). 
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1.3 Unravelling the genetics of schizophrenia and bipolar disorder 
 
1.3.1 Epidemiological studies 
Epidemiological studies on SCZ and BPD have provided the first compelling evidence of a strong 
genetic component in both disorders. The leading observation is that both SCZ and BPD run in 
families (Cardno & Owen, 2014; Smoller & Finn, 2003). First-degree relatives of schizophrenic 
probands have almost 10 times higher risk to develop the disorder compared to the general 
population (Lichtenstein et al., 2009); analogous data have been reported for BPD (Smoller & 
Finn, 2003). Interestingly, risk decreases with the genetic distance from the affected relative 
(Song et al., 2015). The confirmation that familiarity is due to genetic factors has come from twin 
and adoption studies. In multiple cohorts of SCZ and BPD twins it has been observed a significant 
higher concordance in affection status for monozygotic brothers compared  to dizygotic ones 
(Cardno et al., 2002; Kieseppä et al., 2014). Both type of twin pairs are assumed to share the 
same environment, including in utero and perinatal conditions, thus the higher concordance rate 
in genetically identical subjects clearly indicate the role of genes in determining the risk. Similarly, 
adopted away children whose biological parents or siblings have SCZ or BPD have at least a 4-
fold risk to be diagnosed with the same disorder (Lichtenstein et al., 2009), again sustaining the 
importance of genetics over the shared familial environment. 
On the basis of these results, the magnitude of genetic influence have been estimated, by 
statistically modeling liability to disorders. Many studies agree in pointing out that heritability, 
defined as the fraction of phenotypic variance explained by genes, ranges from 60 to 80% for 
both SCZ and BPD (Cardno et al., 2002; Song et al., 2015; Sullivan et al., 2003). The remarkable 
outcome have definitely highlighted that both environmental and genetic factors are involved in 
these psychiatric disorders, but the latter have the stronger impact in determining SCZ and BPS 
susceptibility (Lichtenstein et al., 2009). 
 
1.1.4 Search for common risk variants 
Since the establishment of the high heritability, considerable efforts have been undertaken to 
identify the loci involved in SCZ and BPD and their relative contribution, thus the genetic 
architecture of the disorders. The hypothesis of a major locus with a Mendelian-like inheritance, 
have been almost immediately rejected, because incoherent the high prevalence of the disorders 
in the population (Kerner, 2015). Preliminary investigations have suggested that SCZ and BPD 
are actually polygenic; in addition, the genetic and environmental interplay in defining the 
phenotype clearly classifies SCZ and BPD as complex disorders (Lichtenstein et al., 2009; 
Sullivan et al., 2003). 
13 
 
Two genetic models, initially opposing, have been proposed: the ‘common disease-common 
variant’ and the ‘common disease-rare variant’ (Doherty, O’Donovan, & Owen, 2012). According 
to the ‘common disease-common variant’ hypothesis, the genetic predisposition to SCZ and BPD 
is conferred by multiple alleles with a relatively high population frequency (typically >1%), each 
with a small effect size. Conversely, the ‘common disease-rare variant’ assumption proposes that 
much of the disease susceptibility is due to rare, high-penetrant alleles. The debate around the 
two models has driven the research of genetic factors in the past 20 years.  
The ‘common disease-common variant’ model represented the dominant theory in early phases of 
SCZ and BPD investigation. The presence of risk factors with low penetrance, likely not subjected 
to negative selection, was seen as the most plausible scenario considering such a high and 
constant prevalence of the disorders worldwide (Kerner, 2015). 
The conventional methodological approaches for tracking common variants are association 
studies, that aim at finding alleles significantly more frequent in a cohort of cases versus a cohort 
of controls. First association studies were conducted by genotyping a small number of SNPs, 
usually encompassing a single candidate gene in samples of a few hundred cases and controls. 
These studies have proposed the involvement of a few genes, the most famous ones being 
DISC1 (disrupted in schizophrenia 1), DRD2 (dopamine receptor D2) and COMT (Catechol-O-
Methyltransferase). The initial enthusiasm was followed by an alternation of positive and negative 
replications that challenged the consistency of the results (Farrell et al., 2015).  
 
Research received a new impulse with the development of genome-wide association studies 
(GWASs), that provided the possibility to systematically inspect the ‘common disease-common 
variant’ hypothesis (The Wellcome Trust Case Control Consortium, 2007). GWASs rely on the 
genome-wide genotyping of single nucleotide polymorphism (SNP) markers, feasible with 
microarray technology. Each marker is tested for association and, since SNP distribution is 
pervasive, the entire genome can be interrogated in the same experiment, removing biases of 
candidate-driven analyses. GWASs have thus the advantage of not requiring any a priori 
knowledge on disease biology (Chen et al., 2015; Neale & Sklar, 2015). A fundamental principle 
in these studies is linkage disequilibrium (LD), defined as the genotype correlation between 
different SNPs, generally in close proximity, derived from evolutionary conservation or drift (Neale 
& Sklar, 2015). The degree of LD is measured with the r2 metric, ranging from 0 (no LD) to 1 
(complete LD). LD delineates short haplotype blocks of genotyped and non-genotyped alleles, of 
which the genotyped SNPs are representative (tag-SNPs). Hence the association with a specific 
marker must be intended as the association with the genomic locus tagged by the tested SNP 
(Visscher et al., 2012). The effect size in conferring risk is instead reflected by the odd ratio (OR) 
of allele frequencies in cases and controls. 
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The modest success of the first 
GWASs, where a few or no 
associations were detected 
(O’Donovan et al., 2008; Sullivan et al., 
2008), have depicted a scenario where 
common risk alleles individually have 
very small effects, with typical ORs 
around 1.1 and always inferior to 1.5 
(Doherty et al., 2012; Harrison, 2015). 
Therefore, a large number of these 
susceptibility factors should have been 
implicated in SCZ and BPD etiology. In 
2009, Purcell et al. provided indeed the primary demonstration of the extreme polygenic nature of 
SCZ and BPD (Purcell et al., 2009). Although no single marker could be implicated in this GWAS, 
cases can be reliably distinguished from controls considering the cumulative effect of hundreds of 
potentially involved alleles, weighted for their effect size. This cumulative effect, named polygenic 
risk score, has been also the first proof that common variants contribute to liability. A 
consequence of the presence of multiple, mostly independent, risk factors is the low probability of 
sharing an identical susceptibility allele, causing a high heterogeneity of patients. This suggested 
that the failure of the first attempts was probably due to small sample sizes and highlighted the 
need for large cohorts to reach the required statistical power. (Chen et al., 2015). In light of this 
evidence, worldwide collaborations have been established, the largest and most effective being 
the Psychiatric Genomic Consortium (PGC), founded in 2007 (Sullivan, 2010). From 2011 
onward, the schizophrenia division of PGC (PGC-SZ) started to publish meta- and mega-analyses 
on joint samples, achieving important results (Ripke et al., 2011; Ripke et al., 2013) (Figure1.1). 
Quality criteria were also established to get trustworthy associations: a genome-wide p-value 
threshold of 5x10-8 and a minimum sample size of 10,000 considering cases and controls. The 
effectiveness of these approaches is summarized in the most recent and comprehensive study 
(Ripke et al., 2014), that includes almost all the known SCZ samples of Caucasian ancestry 
worldwide, for a total of 36,989 cases and 113,075 controls. In this mega-analytic GWAS, 108 
independent loci were identified, 83 of which had not been previously reported (see appendix 
7.1). The results also replicated all but 5 known SCZ loci that meet modern quality criteria; 
interestingly, neither DISC1 nor COMT genes, initially retained among the strong candidates, 
found any support. These 108 loci represent today the state of the art on common variants 
involved in SCZ (figure 1.2). 
 
 
 
Figure 1.1: Relationship between sample size increase and detection 
of significant loci in GWASs of SCZ performed by PGC. From Need 
& Goldstein 2014 
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Figure 1.2: Manhattan plot of the largest GWAS on 36,989 SCZ cases and 113,075 controls. Green diamonds indicate the 
108 statistically significant loci. From Purcell et al., 2014. 
 
GWASs on bipolar cohorts have been less successful, a difficulty attributable again to the 
relatively limited number of samples collected so far (Neale & Sklar, 2015). Despite a number of 
published studies, to date only 10 loci have reached genome-wide significance (Chen et al., 2013; 
Cichon et al., 2011; Ferreira et al., 2008; Green et al., 2013a; Green et al., 2013b; Sklar et al., 
2011; Mühleisen et al., 2014) (appendix 7.2). Indeed, the largest study performed to date 
analyzed 9,747 cases and 14,278 controls, detecting 4 loci (Mühleisen et al., 2014); these 
numbers are actually comparable to the ones of the first PGC-SZ publication (Ripke et al., 2011), 
both in terms of samples and identified loci (Figure 1.1). Thus, the increase of sample sizes will 
probably reveal new associations.  
Although GWASs represent a valuable tool for the identification of risk alleles, their main limitation 
is that, once an associated locus is detected, they did not provide information about the functional 
risk variant lying in it. Among the 108 SCZ loci, for instance, 15 have no known gene nearby, and 
36 include more than 3 genes; in addition, for each locus, tens to hundreds of alleles are involved 
(Ripke et al., 2014). This observations suggest that most of the markers showing association are 
not likely the direct causative variant (Chen et al., 2015). On the other hand, the implication of 
other alleles inside a specific locus has proven a hard task, considering the difficulty in assigning 
functional meanings to each sequence change (Need & Goldstein, 2014). Therefore, even if a 
collection of statistically compelling loci is available for both SCZ and BPD, no common allele, or 
gene, has been definitively confirmed to date. 
Another issue arose with the remark that the identified loci could explain only a small fraction of 
the heritability estimated from epidemiological studies. For example, the 108 loci together can 
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account only for 3.4% of the variance in liability due to genetic factors (Ripke et al., 2014). 
Empirical simulations demonstrated that the whole common variants, including those not yet 
identified for power issues, explicate about one third of heritability (Lee et al., 2012; Purcell et al., 
2009; Ripke et al., 2013). Since the currently available microarrays cover about 70% of the 
existing common variation, it’s possible to affirm that common risk alleles can explain from one 
third to a half of the genetic susceptibility to SCZ and BPD (Lee et al., 2012). Half of the 
heritability remains thus theoretically unaccounted. In addition, is has been shown that common 
markers show very little LD with rare variation (Visscher et al., 2012); for technical reasons, then, 
rare alleles are invisible to GWASs and can’t drive any association signal. This have led to the 
conclusion that the ‘common disease-common variant’ model should be integrated with the 
‘common disease-rare variant’ one (Doherty et al., 2012; Sullivan, Daly & O’Donovan, 2012). 
 
1.1.5 Search of rare risk variants 
Following the demonstration that common variants alone are not sufficient to explain SCZ/BPD 
susceptibility , in the last years attention has turned toward the discovery of rare alleles. After re-
evaluation, in fact, also the hypothesis of multiple rare risk factors has been considered 
compatible with common disorders, due to the polygenic inheritance (Kerner, 2015): the high 
prevalence would be a reflection of a large number of different rare variants. These rare alleles 
would be likely more penetrant than common ones, thus negatively selected and maintained at 
low frequencies in the population (George Kirov, 2015). Two types of rare variants have been 
investigated so far: copy number variants (CNVs) and sequence variants. 
 
1.3.2.1 Copy number variants 
CNVs are duplications or deletions of DNA segments with respect to the reference genome, 
usually in contiguous positions. The size of these structural variants ranges from 1 kb to several 
Mb, consequently they’re submicroscopic and hardly identified with classical karyotyping 
techniques (Feuk, Carson, & Scherer, 2006). The majority of CNVs are part of the common 
variation of the human genome, with a frequency of more than 1%, and defined as copy number 
polymorphisms (CNPs) (Malhotra & Sebat, 2012). 
Rare CNVs, instead, have long been known to be involved in neurodevelomental disorders, 
causing intellectual disability and autism spectrum disorder (Malhotra & Sebat, 2012). The 
examination of structural variants in SCZ and BPD have been trigged by some precedents from 
cytogenetic studies: in patients with chromosome deletions of 22q11.2, causing the DiGeorge 
syndrome, schizophrenic symptoms were recurrently found (Murphy, Jones, & Owen, 1999). Also 
DISC1, historically the first SCZ gene, was identified because disrupted by a balanced 
translocation (Blackwood et al., 2001). Moreover, CNVs had the features of potentially high-
penetrant variants because, unlike SNPs, they usually involve several exons or even entire 
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genes, causing rearrangements affecting coding sequences or dosage imbalances. With the 
improvement of genotyping platforms, bionformatic tools have been set up for the detection of 
CNVs exploiting SNP intensity and genotype data. As a result, CNVs have been systematically 
investigated in SCZ and BPD, in parallel with GWASs, and more recently with the aim of formally 
testing the ‘common disease-rare variant’ hypothesis (Malhotra & Sebat, 2012).  
An increased burden of rare (<1%) and large (>100 kb) duplications and deletions in SCZ cases 
compared to controls (Purcell et al., 2008; Walsh et al., 2008). Motivated by this evidence, the 
search of associations with specific CNVs produced great amount of data, the majority of them 
hardly replicated; the main reason for inconsistencies is that these variants are extremely rare, so 
large datasets are required to distinguish truly associated CNVs from neutral ones (Rees et al., 
2014). To date, 11 loci harbouring duplications and/or deletions have been confidently 
recognized, ranging from 120 kb to 4 Mb (Kirov, 2015) (Table 1.1); as hypothesized, their effect 
size is higher than common variants, with ORs from 2 to more than 50 (Kirov, 2015; Rees et al., 
2014). In accordance, the most penetrant SCZ variants known so far are two CNVs, the 3q29 
deletion (estimated penetrance 18%) and the previously cited 22q12 deletion (estimated 
penetrance 12%) (Kirov, 2015). 
Table 1.1: The 11 loci harboring CNVs consistently associated with SCZ. † numbers in brackets report sample sizes. ‡ 
indicates the CNV associated also with BPD. Adapted from Kirov, 2015. 
SCZ patients and, to a lesser extent, BPD subjects show a reduced fitness, thus high penetrant 
variants such as CNVs undergo strong negative selection (Power et al., 2013). Besides, the 
recurrence of specific CNVs and the constant prevalence of the disorders implies that these 
variants are continually re-introduced in populations; consequently, a fraction of rare alleles in 
general must be de novo mutations, rather than inherited from parents. Indeed a high mutational 
rate (1:4000-1:20000 live births) has been reported for CNVs, due to the presence of flanking low-
copy repeats, causing non allelic homologous recombination events (Kirov, 2015). Coherently, de 
Locus 
Size 
(kb) 
N genes 
CNV frequency in % 
ORs for SZ 
(95% CI) 
Controls† 
(47,686–81,821) 
SCZ† 
(12,029–21,450) 
BPD† 
(4,288–9,129) 
1q21.1 del 820 11 0.021 0.17 0.033 8.3 (4.6–15) 
1q21.1 dup 820 11 0.037 0.13 0.099 3.45 (1.9–6.2) 
NRXN1 exonic del Variable 1 0.02 0.18 0 9.0 (4.4–18.3) 
3q29 del 1610 21 0.0014 0.082 0.025 57.6 (7.6–438.4) 
WBS dup 1400 28 0.0058 0.066 0 11.3 (2.6–49.9) 
15q11.2 del 290 4 0.28 0.59 0.17 2.2 (1.7–2.7) 
PWS/AS dup 3610 13 0.0063 0.083 0 13.2 (3.7–46.8) 
15q13.3 del 1350 7 0.019 0.14 0.043 7.5 (4.0–14.2) 
16p13.11 dup 790 8 0.13 0.31 0.011 2.3 (1.6–3.4) 
16p11.2 dup‡ 560 26 0.03 0.35 0.13 11.5 (6.9–19.3) 
22q11.2 del 1240 40 0 0.29 0.012 NA (28.2–∞) 
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novo CNVs have been found to be more frequent in SCZ cases than controls (Kirov et al., 2012); 
these rearrangements have substantiated the previously reported CNV loci (table 1.1). 
The role of structural variants in BPD is more controversial. In measuring CNV burden, opposite 
outcomes have been published (Grozeva et al., 2013; D. Zhang et al., 2009); in any case, the 
load of these variants seems to be lower than SCZ patients, both in terms of quantity and of size 
(Shinozaki & Potash, 2014). Analogously, de novo CNVs are only slightly more frequent in cases 
(Malhotra et al., 2011). CNV distribution in BPD cohorts is similar to the controls (Table 1.1) and 
the only CNV consistently associated is a duplication in the 16p11.2 locus (Green et al., 2016). 
The potential lower pathogenicity in BPD would be also compatible with the lower degree of 
cognitive defects seen in bipolar subjects compared to schizophrenic ones; large and rare CNVs, 
in fact, has often been associated with reduced cognitive performance, not only in pathological 
conditions such as neurodevelopmental disorders, but also in healthy subjects (Kirov, 2015). 
 
1.3.2.2 Sequence variants in case-control samples 
With the advent of next generation sequencing (NGS) technologies, the sequencing of whole 
exome (WES) or even genome (WGS) has become feasible, with affordable costs (Shinozaki & 
Potash, 2014). Sequencing data have permitted for the first time the investigation of a class of 
variants impossible to detect with SNP-genotyping: rare sequence variants, that include single 
nucleotide variants (SNVs) and small insertions/deletion (indels). 
The analysis of such rare alleles in case-control cohorts has proved arduous. As previously 
described for CNVs, in fact, a main issue is the discrimination of low frequency variants from 
neutral ones. Additionally, unlike structural variants, sequence variants have shown an 
unexpected heterogeneity (Purcell et al., 2014). Thus huge samples sizes are necessary to 
achieve sufficient statistical power; for this reason, association studies with sequencing data have 
been mainly performed so far on schizophrenic cases. 
To overcome these problems, first studies focused on the identification of de novo coding 
mutations in family trios of affected probands with unaffected parents. Justified by the hypothesis 
of a balance of negative selection, the approach offers in fact an important technical advantage: 
the possibility to focus on a small subset of variants. Several works have supported an increased 
frequency of potentially damaging de novo alleles in SCZ probands compared to controls 
(Awadalla et al., 2010; McCarthy et al., 2014; Xu et al., 2012). These results have been though 
challenged by the largest study performed so far, involving 617 SCZ trios and 731 control ones 
(Fromer et al., 2014). Fromer and colleagues detected no increased rates of de novo mutations in 
cases, rather an enrichment of genes involved in synaptic functions among the ones affected by 
these class of mutations. Beside this striking result, no single variant or gene could be 
significantly associated with the disorder. 
Despite their proven involvement, anyway, de novo mutations don’t explain the high heritable risk 
of SCZ. In this regard, the only real attempt to investigate all rare variants, including the inherited 
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ones, was published in 2014 (Purcell et al., 2014). In this milestone paper, Purcell et al. 
demonstrated a polygenic burden of rare disruptive alleles in SCZ patients by comparing WES 
data from 2,536 cases and 2,543 controls. Interestingly, this burden was driven by genes in 
synaptic processes, indicating that rare variants could actually have a role in SCZ etiology. 
Analogously to de novo approaches, however, no single allele could be significantly associated, 
even when restricting the analysis to subsets of genes functionally relevant with the disorder. 
Therefore, notwithstanding the great potential, the utility of case-control cohorts in detecting rare 
risk factors is limited with actual sample sizes and significant results can be detected only when 
collapsing variants at gene levels.  
 
1.3.2.3 Sequence variants in population- and family-based samples 
As outlined in the previous paragraphs, research of genetic risk factors for SCZ and BPD has 
mainly focused on large case-control cohorts. But considering the emerging limitations in the 
context of rare susceptibility variants, familial sample gained an increasing importance. Indeed, 
multigenerational families with several affected individuals offer some advantages to study rare 
variants as linkage analyses can be exploited to track candidate loci carrying risk alleles. 
Interesting results have been achieved for example for Alzheimer’s disease, again after the 
discovery of uncommon familial cases with autosomal dominant pattern of inheritance (Sullivan et 
al., 2012). 
Several genome-wide linkage scans on familial samples have been published both for SCZ and 
BPD each reporting suggestive loci, hardly replicated between studies (Lewis et al., 2003). These 
results have stressed once more the high genetic heterogeneity of these disorders, hampering the 
outcome of linkage analyses, unable to detect a single, segregating major gene (Neale & Sklar, 
2015).  
In this context samples coming from genetic isolates would provide potential advantages. A 
genetic isolate is a population that, for geographical and/or cultural reasons, has undergone a 
very low admixture (Escamilla, 2001). Isolates generally originated from a small number of 
founders who  experienced a marked expansion, accompanied by high rates of inbreeding. Since 
all the alleles descended from a few ancestors, these samples are characterized by a reduced 
genetic variability and by unique allele sets (genetic drift) (Peltonen et al., 2000). In particular, rare 
variants carried by founders, if not negatively selected, are pushed to higher frequencies; this is 
true also for disease variants, as shown by the higher prevalence of some rare disorders in 
specific isolates, such as multiple sclerosis in Italy in the Sardinia population (Sotgiu et al., 2004). 
The diminished genetic heterogeneity and the enrichment in some rare susceptibility factors make 
population isolates fine opportunities to study simplified models of complex disorders. Moreover, 
even environmental and societal components are likely more homogeneous than in outbred 
populations, reducing possible biases introduced by non-genetic effects (Varilo & Peltonen, 
2004). Sample sizes are often too low to perform powerful association studies, but the common 
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ancestry permits the use of distinct approaches for mapping disease loci, based on the 
identification of haplotypes shared by affected subjects. 
Population-wide investigations has been hardly ever undertaken and in practical the success of 
these approaches has relied on the collection of multiple pedigrees with genealogical ties. In 
these samples, linkage analyses has been effective in exposing rare causative genes for 
Hirschsprung disease in Mennonites, a population from North America, and nonsyndromic 
deafness in Bedouins from Israel. These peculiar samples showed uncommon Mendelian-like 
segregations of these complex disorders, that facilitated the discovery of high-penetrant risk 
factors and initiated the unraveling of their etiology (Peltonen et al., 2000). 
For SCZ and BPD, the application of such approaches has been more trivial, as no Mendelian-
like forms have ever been described (Sullivan et al., 2012). The hypothesis was confirmed by 
recent works on pedigrees for both SCZ (Timms et al., 2013) and BPD (Georgi et al., 2014), 
showing different segregating loci. In the work of Georgi and collaborators, a particularly 
interesting dissection of linkage results in a large Old Order Amish pedigree revealed not only the 
presence of several linkage signals within and across nuclear families, but also that multiple 
haplotypes contributed to single linkage peaks (Georgi et al., 2014). In addition, each of the 
candidate risk haplotype exhibited incomplete penetrance. Thus, even in this well characterize 
homogeneous population, BPD has a polygenic inheritance typical of a complex disorder. 
 
Despite the proven complexity, the potential of these type of samples has been unfolded with the 
advent of NGS; the techniques have provided the chance to combine segregation approaches 
and WES or WGS to obtain a comprehensive view of possible risk factors, necessary to model 
risk. The prioritization of variants according to the sharing in patients has yielded in general to a 
ten of candidate alleles per pedigree, selected for further investigations (Cruceanu et al., 2013; 
Georgi et al., 2014; Timms et al., 2013). Again the variants were not always shared by all the 
affected individuals and sometimes present also in non-affected subjects, coherently with the 
complex inheritance (Cruceanu et al., 2013; Georgi et al., 2014). 
A further conceptual improvement came with the last works, which finally attempted to explore the 
polygenic nature of BPD, focusing on the mutational load of a pedigree. Results revealed multiple 
rare damaging variants in the same patients, affecting genes involved in the same biological 
processes (Ament et al., 2015; Kerner et al., 2013). Although preliminary, this studies have shown 
the potential of family- and population-based samples to define sets of rare alleles conferring risk 
to SCZ and BPD, thus providing realistic models for these complex disorders. 
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1.1.6 The genetic overlap between schizophrenia and bipolar disorder 
Beside the difficulties in defining specific risk factors, genetic studies have consistently converged 
on an overlap between SCZ and BPD. First evidence came from epidemiological studies, showing 
that first degree relatives of schizophrenic patients have also a 4-fold risk of developing BPD; the 
opposite was also true (Lichtenstein et al., 2009). 
Subsequently, the findings have been further substantiated by molecular genetics, as the same 
factors have been repeatedly reported to 
confer susceptibility for both the disorders 
(Smoller et al., 2013). Moreover, the polygenic 
risk score proposed by Purcell et al, when 
calibrated on SCZ samples, could efficiently 
predict case-control status non only in SCZ 
cohorts but also in BPD ones (Purcell et al., 
2009). This indicated that some common risk 
variants have pleiotropic effects for SCZ and 
BPD. Finally, the 108 loci currently associated 
with SCZ, include 3 of the 6 genes significant 
also for BPD (NCAN, TRANK1 and 
CACNA1C) (Ripke et al., 2014). 
In light of these observation, the cross-disorder 
group of the PGC used common SNPs to 
estimate the genetic relationships between the 
five major psychiatric disorders: schizophrenia, bipolar disorder, major depressive disorder 
(MDD), autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD) (Lee 
et al., 2013). Results revealed that almost all 
the disorders share a fraction of genetic 
etiology, and that the overlap was particularly 
important between SCZ and BPD, with a 
genetic correlation of 0.68. Thus about 70% of 
common risk variation is shared between the 
two disorders (Figure 1.3). Similar analyses 
have not been performed yet for  rare variants, 
as these are likely more private and difficult to 
detect in different samples. More general 
estimations have however been calculated 
with family studies, all converging on a co-
heritability of at least 60% (Lichtenstein et al., 
2009; Song et al., 2015). 
Figure 1.3: SNP-based heritability and co-
heritability estimated for 5 major psychiatric 
disorders. SCZ and BPD show the highest 
genome-wide pleiotropy, as their co-heritability is 
about 70% of their individual heritability. From Lee 
et al., 2013. 
Figure 1.4 .Models of the possible biological relationships 
underling clinical phenotypes. Each circle represent a group 
of genes influencing a specific phenotype, defining a 
biological entity. It is still unclear whether the clinical 
spectrum is determined by multiple, overlapping entities or 
by a structured continuum of disease processes. From 
Craddock et al., 2009. 
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Despite the high overlap, SCZ and BPD can’t be considered identical, for several reasons. Firstly, 
cross-disorders relative risk in families is always inferior than the within-disorder one. Secondly, 
some of the variants are specifically associated with a phenotype; CNVs for example, seem to 
play a minor role in BPD than in SCZ. Consequently, it’s realistic to speculate that there must be 
some characteristic genetic factor driving the outcome towards psychosis or mood symptoms. 
Nonetheless, the number of distinct biological entities underling the clinical spectrum is still yet to 
be determined (Figure 1.4) (Craddock, O’Donovan, & Owen, 2009). 
 
1.4 The emerging picture on schizophrenia and bipolar disorder 
20 years of genetic studies have led to significant improvements in understanding the genetic 
architecture of SCZ and BPD. It’s clear now that empirical data support both the ‘common 
disease-common variant’ and the 
‘common disease-rare variant’ models 
(Sullivan et al., 2012). The allelic 
spectrum encompasses so far common 
polymorphisms, rare sequence variants 
and even rarer CNVs (figure 1.5). As 
predictable, the frequency of risk 
variants has an inverse relationship with 
penetrance, with common variants only 
slightly increasing the risk for the 
disorders and rare variants having 
instead higher effect sizes(Mowry & 
Gratten, 2013). The current evidence 
likely excludes the existence of rare, 
almost completely penetrant alleles 
(Mendelian) as well as of common 
polymorphisms with moderate or large effects (Sullivan et al., 2012). However, the exact total 
number of loci is still unknown and, assuming an heritability of 80%, more have to be identified. 
Moreover, while common variants account for about 50% of heritability (Lee et al., 2012), the 
precise contribution of rare alleles has yet to be determined. Finally, whereas several loci have 
been confidently reported, no single variant has been definitely implicated (Harrison, 2015; Neale 
& Sklar, 2015).  
Beside the cited limitations, genetic studies have provided remarkable convergence on some 
biological networks, clearing the ground for the discovery of possible mechanisms for the etiology 
of the disorders. First supports have come for the original proposed hypothesis for SCZ, positing 
a hyperactive dopamine transmission. The theory has been formulated after the discovery of the 
first antipsychotic drugs, in early 1950s, since these act mainly as antagonist of dopamine 
Figure 1.5: Allelic spectrum of risk variants identified for 
SCZ.  From Mowry and Gratten, 2013. 
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receptors, in particular type 2 (D2) (Neale & Sklar, 2015). Interestingly, DRD2 gene, encoding for 
D2 receptor, maps in one of the 108 loci associated to SCZ (Ripke et al., 2014), in line with the 
initial assumptions. 
 
 
But another hypothesis has recently received much attention: the glutamatergic synapse 
dysfunction. Indeed, the known 108 loci include several genes for glutamate receptors, as GRM3, 
(metabotropic), GRIA1 (AMPA, ionotropic) and GRIN2A (NMDA, ionotropic) (Ripke et al., 2014). 
NMDA receptor signaling, in particular, has become a major candidate pathway for SCZ liability. 
NMDA receptors are ionotropic Ca2+ channels, activated upon membrane depolarization, 
generally after the opening of AMPA receptors. Glutamate binding on activated NMDA receptors 
causes an influx of Ca2+, triggering several signaling cascades within the neuron (Figure 1.6). On 
one side, this results in an enhancement expression of AMPA receptors, leading to a long-term 
increase of synaptic strength (long-term potentiation). Then again, the transcription of activity-
regulated cytoskeleton-associated scaffold protein (ARC) is induced; ARC complex has a major 
influence on dynamics of dendritic spines through the remodeling of actin cytoskeleton. These 
glutamate receptors are thus key regulators involved in persistent synaptic changes, determining 
structural and molecular plasticity, fundamental for memory and cognition, but also for the 
formation of brain connectivity during development. (Hall et al., 2015). Consistently, it has now 
been established from postmortem brain studies, that SCZ patients show morphological 
Figure 1.6: Synaptic plasticity modulated by NMDA receptors. From Hall et a., 2015 
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alterations in dendritic spines, specifically a reduction in spine density and arborization in the 
cortex (Moyer et al., 2015). The current model proposes a hypofunction of NMDA receptor in 
SCZ, causing a reduced plasticity. Indeed, pre-frontal cortex and hippocampus of SCZ patients 
display a decreased expression of these glutamate receptors, both at the transcriptional and the 
translational level (Weickert et al., 2013). Moreover, NMDA antagonists can induce also 
schizophrenia-like psychotic symptoms in humans and rodents (Zhang et al., 2016). Three main 
works have further provided genetic support for this hypothesis. de novo CNVs (G Kirov et al., 
2012), de novo sequence variants (Fromer et al., 2014) and overall sequence variants (Purcell et 
al., 2014) associated with SCZ have been found to significantly affect NMDA receptor network. 
More in detail, the results evidenced an enrichment in proteins belonging to the ARC and the 
PSD-95/Dlg4 complexes. The latter is composed by several proteins located in the postsynaptic 
density (PSD) region, which have a major role in modulating NMDA receptor signal transduction 
and activity. 
On the same line, voltage-gated Ca2+ channels (VGCCs) have been repeatedly implicated in 
SCZ. Purcell et al. reported a higher burden of disruptive mutations in VGCC genes in SCZ cases 
(Purcell et al., 2014); additionally, 3 of such genes overlap the 108 SCZ loci (Ripke et al., 2014). 
These channels mediate the entrance of Ca2+ in excitable cells, above all neurons, after 
membrane depolarization. In glutamatergic synapses, this regulates axonal growth and guidance, 
mediated by glutamate signaling (Neale & Sklar, 2015). In a more general view, thus, the 
emerging hypothesis for SCZ is an impairment in neurodevelopmental processes in the formation 
of neuron connectivity. Indeed, pre-natal and peri-natal complications are recognized as 
environmental risk factors, that could act in concomitance with a genetic susceptibility to cause 
the onset of SCZ (Kotlar et al., 2015). 
The majority of the reported theories have been elaborated from SCZ studies, since many more 
loci have been discovered compared to BPD. Although it’s still unclear whether these observation 
can be extended also to this second disorder, the clinical and genetic overlap suggests that 
common mechanisms may be involved (Neale & Sklar, 2015). Definitely, some recent evidence 
sustain this speculation. CACNA1C gene, belonging to the VGCC class, is now significantly 
associated also with BPD (Ferreira et al., 2008) and BPD pedigrees have an increased burden of 
rare variants in VGCCs and in neuronal ion channels in general (Ament et al., 2015). 
Glutamatergic synapse seems to be also involved, but NMDA receptors have a specular role for 
depressive symptoms with respect to SCZ, as antagonists (especially ketamine) can effectively 
counteract these specific signs (Hashimoto et al., 2013). Brain abnormalities have been less 
investigated, but diffusion tensor imaging experiments have shown a reduced connectivity 
between brain areas, particularly with prefrontal cortex (Wessa et al., 2014). Further insights are 
though required to formulate a more organic hypothesis on BPD pathogenesis 
Concluding, genetic investigations have lead to unprecedented advances in understanding the 
biology of SCZ and BPD. Many questions, however, are still to be solved, starting from the 
genetic architecture, the pathogenetic mechanisms, that are still hypothetic, to finally unravel the 
interplay between genetic and environmental factors that determines risk (Harrison, 2015). 
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2. Aim of the research 
This study aims at investigating the genetic component  of schizophrenia (SCZ) and bipolar disorder 
(BPD) in a unique population sample, constituted by several families with a high recurrence of the two 
psychiatric disorders. Since all the patients have a common ancestry from a closed community, the 
working hypothesis is an enrichment of rare alleles with large effects on disease risk. On these 
premises, this sample offers the opportunity to examine the role of rare variation in SCZ/BPD 
etiology. Several studies have in fact evoked the involvement of rare alleles in these psychiatric 
disorders, but their precise impact has not yet been determined, nor specific genes have been 
identified. 
These limited results derive from the general difficulties in implicating rare variants in heterogeneous 
cohorts; as a consequence, more homogenous samples, especially family-based ones, have gained 
an increasing importance. In these context, however, the majority of available approaches have been 
developed for Mendelian disorders and are less effective when dealing with complex traits. Indeed, 
the same approaches had been previously unsuccessful in this sample. For this reason, a novel 
strategy was envisioned, combining Identity-By-Descent (IBD) mapping and Whole-Exome 
sequencing (WES). Each of the steps required the development of a customized bioinformatic 
pipelines and their integration to those already available.  
 
In a preliminary phase of the project, the role of Copy Number Variants (CNVs) wanted to be 
evaluated, since these structural variants have been implicated in psychiatric disorders, particularly in 
SCZ. 
The following steps were then directed to the set up of IBD analysis, from the selection of the most 
suitable algorithm to the processing of the output. The final outcome wanted to be a map of the 
shared haplotypes across the genome, for the identification of loci particularly common in patients. 
More in details, the focus was put on the tracking of loci encompassing multiple pedigrees, thus 
accounting for a high number of patients. The last phase envisaged the examination of WES data 
from a subset of patients, selecting rare or novel variants mapping in IBD haplotypes. Subsequently, 
the IBD map was intended as an instrument to infer the sharing of each mapped variant in the entire 
population and the segregation within each pedigree. The final goal was then to establish whether 
these variants were affecting specific biological functions and to provide a set of candidate genes 
involved in SCZ and BPD. 
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3. Materials and Methods 
3.1 Sample description 
Sample collection was performed in collaboration with the Center of Mental Health of Chioggia. SCZ, 
BPD and SZA were diagnosed according to DSM-IV criteria (American Psychiatric Association, 
2013), after independent evaluations from two expert psychiatrists. All patients had been hospitalized 
and medical records were available for each of them. Families were collected whenever at least an 
additional member (first or second-degree relative) met the DSM-IV diagnostic criteria. Informed 
consent was obtained for all participants and the study was approved by the Medical Ethic Committee 
of Chioggia, in accordance with current legislation. 
Chioggia is a small town built in a group of islands of the southern Venetian lagoon. Total population 
size is around 60,000 inhabitants; the collected sample, however, belonged to groups of families 
living in the old parts of the town. More in details, individuals came from two islands, the main 
Chioggia and its neighborhood Sottomarina (figure 3.1). Pedigrees were tracked by a genealogist 
back to four/five generations, thanks to church registers and demographical records, to confirm the 
origin from the historical population. 
 
For socio-cultural reasons, Chioggia had been particularly secluded until 50 years ago; as a proof, 
several cases of homonymy are observed and 3 family names account for about 50% of the entire 
population (Gessoni et al., 2010). This evidence suggests a high rate of endogamy, thus a more 
homogeneous genetic background. Interestingly, the prevalence of the psychiatric disorders of the 
SCZ/BPD spectrum seems peculiarly elevated, twice as high as the surrounding geographical areas. 
These features overall indicate a possible enrichment of rare, high-penetrant susceptibility alleles, 
making this sample ideal for the investigation of genetic etiology of the disorders. 
Chioggia  Sottomarina 
Figure 3.1: Aerial view of Chioggia and 
Sottomarina, in the Venetian lagoon. Yellow 
outlines indicate the old parts of the town, while 
yellow dots represent approximately where the 
majority collected samples reside. 
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The original sample includes more than 200 patients; the subset presented in this study is composed 
by a total of 197 subjects, of which 161 affected. 90 individuals were diagnosed with SCZ, 50 with 
BPD and 21 with SZA. 106 patients belonged to 36 pedigrees, together with 22 healthy relatives 
(figure 3.2). Additionally, 24 cases had a known family history of the disorders, but no other family 
member was available for study. On the basis of clinical assessment, 42% of the total pedigrees 
could be classified as schizophrenic (SCZ patients only), 15 % as bipolar (BPD patients only) and 6% 
as schizoaffective (SZA patients only); remarkably, the remaining 37% of families (22 pedigrees) 
comprised multiple disorders (SCZ and BPD or SCZ and SZA), supporting the overlap between SCZ 
and BPD. Further 31 isolated cases were also analyzed and finally, 14 healthy controls from the 
same population were collected.DNA was extracted from peripheral blood or buccal swab , with 
classical phenol-chlorophorm protocols.  
 
3.2 Preliminary investigations on the population sample 
Prior to this work, several investigations had been already performed on this sample. Since some of 
the pedigrees showed an apparent matrilineal transmission of the disorders, a possible role of 
mitochondrial DNA was analyzed (Bertolin et al., 2011). Haplogroups were determined in 89 patients, 
but their frequencies didn’t significantly differ from the Italian ones, excluding a haplogroup-derived 
susceptibility. Moreover, the complete mitochondrial genome sequence was obtained for 27 affected 
subjects, but none of the identified variants had a predicted functional effect. Thus, point variation in 
mitochondrial genome could not account for the disorders in this population. Attention had thus turned 
to nuclear genome and a genome –wide linkage analysis based on SNP markers was performed. 
SNP genotyping data were obtained for the 197 samples using Illumina 370K-quad chip, for the 
detection of about 370,000 markers. 221,764 autosomal markers were selected after quality filtering, 
to remove SNPs showing Mendelian inconsistencies or with high rates of genotyping failures. Both 
parametric, under dominance or recessive models, and non-parametric, model-free settings have 
been considered. Some LOD signals emerged, but none of them was statistically significant. 
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Figure 3.2 : Pedigrees of the 36 families analyzed in the study. Pure schizophrenic families are displayed on the bottom right part, pure bipolar on the bottom 
left and mixed families on top. SCZ: schizophrenia; BPD: bipolar disorder; SZA: schizoaffective disorder; NS: referred affected with either SCZ or BPD. 
Legend: 
NS 
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3.3 Copy Number Variants 
CNVs calling was performed by the CNV-webstore online tool (http://cnv-webstore.ua.ac.be/cnv-
webstore/) (Vandeweyer et al., 2011), on the basis SNP-genotyping data. Necessary input files were 
extracted from Illumina standard output thanks to three PERL scripts provided by the tool itself. The 
entire SNP set was considered on the 197 available samples. After analysis, 32 samples were 
excluded for quality reasons. 
CNV-webstore integrates three algorithms for the detection of CNVs: QuantiSNP (Colella et al., 
2007), PennCNV (Wang et al., 2007) and VanillaICE (Scharpf et al., 2008). A majority vote approach 
was chosen, thus only CNVs reported by at least two algorithms were retained. All the methods are 
based on Hidden-Markov Models for the prediction of copy number status exploiting two main 
parameters: the normalized profile of SNP intensity signals (LogR ratio) and the proportion of signal 
attributed to the minor allele (BAF) for each SNP. For example, stretches of SNPs with LogR ratio 
inferior to 0 and BAF of 0 or 1 (homozygous SNPs) are called as deletions (copy number=1); 
analogously, LogR ratios greater than 0 and BAF of 1/3 or 2/3 indicate a duplication (figure 3.3). 
Boundaries of differentially called CNVs are automatically adjusted by CNV-webstore. 
The overlap between the entire collection of detected CNVs and the International Schizophrenia 
Consortium (ISC) dataset (Purcell et al., 2008) was explored converting all data in UCSC Genome 
Browser custom tracks. 
For the identification of rare or novel CNVs, a quality filtering was performed in order to focus on 
reliable variants. On the basis of chip characteristics, the following thresholds were imposed: ≥10 
consecutive SNPs, ≥30 kb size, an average density of 1 SNP every 10 kb and an average score of 
0.5 per SNP, as calculated by the three algorithms in CNV-webstore. A consensus was then derived 
across the different samples. The resulting variants were searched in DGV (database of genomic 
variants, http://dgv.tcag.ca/dgv/app/home) and HapMap (http://hapmap.ncbi.nlm.nih.gov/) resources. 
Novel or rare variants were initially defined as those with a <70% overlap with a reported DGV 
polymorphism. Subsequently, retained CNVs were confronted with HapMap data and variants largely 
reported were excluded. All steps were realized by PERL scripts. 
 
 
Figure 3.3: Examples of CNV detection from LogR ratio and B-allele frequency estimated from SNP-genotyping data. As 
illustrated in panel a (adapted from Wang et al., 2007), normal copy numbers (2 copies) are characterized by a LogR of 0 and 
by B-allele frequencies (BAFs) distributed across three possible values: 0 (AA genotype), 0.5 (AB genotype) and 1 (BB 
genotype). Panel a shows also a duplication (3 copy CNV), evidenced by increased LogR ratio values and anomalous BAFs 
(0.33 and 0.66 for AAB and ABB genotypes respectively). In panel b (adapted from Colella et al., 2007)is instead represented 
a single deletion (1 copy CNV), revealed by a negative LogR ratio and the absence of heterozygous genotypes (BAF ≠ 0.5). In 
panel c is shown a deletion (1 copy CNV) as displayed in CNV-webstore. 
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3.4 IBD analysis 
Two different free programs have been evaluated for IBD analysis: GERMLINE (Gusev et al., 2009) 
(http://www.cs.columbia.edu/~gusev/germline/, v1.5.1) and Relate (Albrechtsen et al., 2009) 
(http://www.popgen.dk/software/index.php/Relate, v0.998). Both methods require SNP-genotyping 
data as input, in plink file format, and were run on the 221,764 good quality markers previously 
selected. For technical reasons, again only autosomes could be investigated. The algorithms are 
based on completely different principles for the detection of IBD regions between all the possible 
pairs of individuals. GERMLINE relies on an initial phasing step, implemented with BEAGLE software, 
when SNP genotypes are converted into haplotypes. Since multigenerational pedigrees were 
available, the phasing results could be checked independently by alternative software (e.g. 
GeneHunter); GERMLINE procedure was found to be often imprecise. Unfortunately, this critical step 
compromises the calling of IBD regions, that is obtained by simply aligning the phased haplotypes to 
detect identical blocks. Consequently, Relate was selected as the best performing software. Relate 
exploits a first order Markov chain to provide posterior probabilities of IBD status for each marker, on 
the basis of 3 main parameters:  
- a: rate of change between IBD states from a marker to the next. 
- k: vector of 3 elements, k0, k1, k2, indicating the overall ratio of IBD0, IBD1 and IBD2 
- ε: genotyping error rate 
 
The complete list of options and parameters used for the final analysis are listed in table 3.1. Each of 
the option was set up by running preliminary tests on sample subsets. Besides ε, that must be 
indicated, all the other parameters (a, k) were chosen to be optimized by the algorithm itself 
(doParameter calculation=0, fixA=0); even the estimation of a from the overall allele sharing between 
a pair was excluded (calculateA=0), since it would be efficient only with a single nuclear family or very 
distantly related individuals. Also IBD2 status was considered (fixK2=0). As suggested by the manual 
in case of calculate=0, times_to_run and times_to_converge were set to 10 and 5 respectively, to 
reach the necessary convergence of the algorithm. 
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Option/Parameter Value Notes 
allpairs 1 1= run all pairs; 0= run a single pair 
pair[0] 0 first individual of the pair (only if allpairs is set to 0) 
pair[1] 1 second individual of the pair (only if allpairs is set to 0) 
double recombination 0 rates of double recombination 
LD 0 measure to calculate LD (LD=0=rsq2; LD=1=D) 
min 0.01 minimum minor allele frequency allowed 
alim[0] 0.001 Lower limit of the range of a 
alim[1] 1 Upper limit of the range of a 
doParameter calculation 0 1= use the specified parameters (par[0,1,2]); 0= optimize parameters 
par[0] 0.3 a (only used if doParameter is set to 1) 
par[1] 0.25 k2 (only used if doParameter is set to 1) 
par[2] 0.5 k1 (only used if doParameter is set to 1) 
ld_adj 1 1=use the pairwise emission probabilities to correct for LD; 0=no correction 
epsilon 0.01 ε 
back 25 number of SNPs to condition on to accomodate LD 
doPrune 1 1=prune SNPs to remove LD; 0=no pruning 
prune_value 0.5 maximum rsq2 accepted between SNPs (only if doPrune is set to 1) 
fixA 0 1=use fixed values for a; 0=optimize a 
fixA_value 0 fixed a value (only if  fixA is set to 1) 
fixK2 0 1=use fixed values for k2; 0=optimize k2 
fixK2_value 0 fixed k2 value (only if  fixK2 is set to 1) 
calculateA 0 1=estimate a from overall allele sharing; 0=optimize a 
phi_value 0.013 recombination rate (Morgans/Mb) 
convergenge_tolerance 0.1 parameter for convergence of optimization 
times_to_converge 5 The number of times the optimization should reach the same optimum 
times_to_run 10 The maximum number of times the optimization is run 
back2 50 debuggin parameter 
Table 3.1: Parameters for Relate analysis 
Immediately before proper IBD analysis, Relate executes a SNP pruning step to remove markers in 
strong LD. LD blocks might be: (I) local associations of alleles that, as a consequence of genetic drift, 
are particularly common in the population; for these SNPs it’s impossible to distinguish identity by 
state (IBS) from IBD; (II) traces or very ancient ancestors. The aim of the approach was to identify 
haplotypes inherited by relatively recent ancestors, like population founders, thus LD blocks would 
have represented a source of false positive results. LD pruning was carried out (doPrune=1) with a 
threshold of 0.5 (prune_value=0.5): if SNPs with a genotype correlation (measured as r2, LD=0) 
greater than 0.5 were present, only one representative SNP would have been retained. LD profile 
was calibrated on the entire sample using sliding windows of 25 markers (back=25), as 
recommended with approximately 250,000 input markers. By default, back2 was set to 50, twice the 
value of back. This configuration yielded 135,702 markers after pruning. Analysis was run on a total 
of 19,306 pairs of 197 individuals (allpairs=1). 
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The output is structured as a text file (.post) with 2 rows per pair and a column per marker. These 
data were used to infer the three possible IBD status: 
 IBD0: the two subjects share no IBD. 
 IBD1: the two subject share one IBD haplotype on one homologue 
 IBD2: the two subjects share two IBD haplotypes both the homogues 
The first row of the output file lists the posterior probabilities for each SNP to be IBD0, while the 
second row report the probabilities of IBD1 status. Probabilities of IBD2 status were instead 
calculated for each pair, as the complementary to 1 of the IBD0 and IBD1 values. An ad-hoc pipeline 
based on PERL scripts was develop to process this data and obtain a list of IBD regions. 
 
IBD regions were called according to the trend of IBD0, IBD1 and IBD2 probabilities across the 
markers. IBD status was assigned to every SNP using a threshold of 0.98. The method accounted 
also for possible fluctuations: in a context of markers with defined status (thus when at least one SNP 
exceeded the probability of 0.98), the threshold was lowered to 0.70 for that specific status. IBD 
regions were then defined as segments of consecutive IBD1 or IBD2 markers. Blocks of undefined 
markers (e.g. markers whose probabilities never reached the imposed thresholds) were by default 
considered as IBD0, therefore not IBD. These blocks were particularly observed close to centromeres 
or telomeres on in regions of transition between status.  
 
3.5 Estimation of genetic similarities from IBD data 
Genetic similarity was measured through the relatedness coefficient (r), calculated as the sum of the 
sizes of IBD1 regions and twice the sizes of IBD2 regions over the total genome captured by the 
135,702 analyzed markers. The latter was estimated to be 2,784,183,496 bp, approximately the size 
of euchromatic genome (2.88 Gb) (Platzer, 2006). r was estimated for all the possible pairs and 
compared to expected values. To evaluate the performance of this method in unrelated individuals, a 
further sample of 33 subjects of Italian origin was investigated. SNP- genotyping was performed with 
the same platform and IBD analysis was carried out on the same 135,702 markers. To obtain this 
configuration, the subset of markers was previously extracted from the total set, then Relate was run 
avoiding the pruning step (doPrune=0). Output processing and calculation of genetic similarity were 
accomplished with the identical approaches. Significance of differences in relatedness between the 
two unrelated cohorts were calculated with Welch two-sample t-test. To evaluate the degree of 
kinship existing between unrelated pairs, expected genetic similarity was calculated for increasing 
number of elapsing generations and the number of pairs with corresponding r was counted.  
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3.6 Cluster Analysis 
All the steps of cluster analysis were performed with R software (https://www.r-project.org/). From r 
coefficients, a matrix of genetic distances was generated for 115 ‘family founders’, where distances 
were simply calculated as:  
d=1-r 
First, multidimensional scaling (or principal coordinates analysis) of the obtained matrix was 
calculated on 2 dimensions, and resulting values for each pair were plotted. 
Second, 53 more samples were added, including the 33 individuals of Italian origin and 20 HapMap 
individuals of 4 different ancestries: 5 Yoruba (Africa), Yoruba (Africa), Han Chinese in Beijing 
(China), Japanese in Tokyo (Japan) and Europeans in Utah (Europe). IBD analysis and genetic 
similarity calculations were carried out with the same strategy adopted for the 33 Italians. After 
obtaining the total matrix of genetic distances, including 168 subjects, hierarchical clustering was 
achieved with ward method and results displayed in a dendrogram. Significance of Chioggia and 
Sottomarina clusters was calculated with a generalized linear model with the known origin as 
covariate. (didascalia: the covariate origin could significantly predict the cluster). 
 
3.7 Haplotype clustering 
Haplotype clustering conceptually consists in identifying groups of individuals sharing identical 
haplotypes, starting from pairwise-detected IBD regions. Clustering was based on the following 
logical rule: if the same genomic region was found IBD in all the possible pairs of at least 4 
individuals, then a common haplotype had to be assumed (see figure 4.7 for details). The entire 
procedure was developed using PERL scripts. Briefly, all genome was scanned by a sliding window 
of 200 SNPs and a pace of 50 SNPs. Haplotype clustering was performed each time considering all 
the IBD regions overlapping more than 50% of the window; this ensured the effective overlap 
between the pairwise IBD segments, avoiding wrong outcomes. With this approach, a size exclusion 
of 100 markers, was also automatically introduced, thus selecting only the larger, most reliable IBD 
calls. In every window, the clustering algorithm was run three times, each time randomly choosing the 
order of segments/pairs to be analyzed. A consensus was then calculated within windows, merging 
clusters with more than 85% identity. These last steps were thought to counteract possible false 
negative calls, causing cluster interruptions due to the missing detection of an IBD region between a 
pair; random order in clustering should in fact break the cluster in different ways, then joined in the 
following stage. Finally, a inter-window consensus was obtained, merging clusters differing in less 
than 20% of members and in less than 15% in size, eventually estimating the genomic extension of 
shared haplotypes. 
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For every cluster, a series of family-based scores were calculated, indicating the number of families 
and the fraction of the patients per nucleus that were included. In addition, the relative amount of 
subjects from the two subpopulations (Chioggia or Sottomarina) and the percentage of patients with a 
specific disorder (SCZ, BPD or SZA) were computed. 
 
3.8 Whole-exome sequencing and variant filtering 
Whole-exome sequencing was carried out on 17 selected patients with IonTorrent® technology (Life 
Technologies) on IonProton™ platform. Template preparation, sequencing reaction, reads alignment 
and variant calling were performed in collaboration with CRIBI (Centro di Ricerca Interdipartimentale 
per le Biotecnologie Innovative), from the University of Padova. Target enrichment was achieved by 
multiplex PCR with Ion Ampiseq™ Exome RDY Kit. 
Classical annotation procedure executed by IonReporter™ software (v 4.4) was improved thanks to 
the development of a pipeline, based on PERL scripts. The approach was set up after the surfacing of 
some issues related to the presence and the frequency of variants in reference databases:  
1. Annotation of frequencies with IonReporter™ was sometimes missing or inaccurate. 
2. In annotation procedure, only genomic position of variants was considered, without any 
actual check between the variant and the alleles reported in databases. As a consequence, 
any variant in the same position of a known SNP would have been always called as a 
polymorphism, even if the variant itself had never been observed before. 
3. This last issue derived from inaccuracies in the reference human genome, where sometimes 
the reference allele for a SNP is not the most frequent one. Thus, whenever a SNP is not a 
common polymorphism, the reference becomes a potentially interesting allele, but any caller 
would never detect it as a variant. This situation has two main drawbacks. First, the reported 
minor allele frequency (MAF), generally used for filtering, refers to the reference and not to 
the detected variant. Typically, an individual might look homozygous for a rare allele, but is 
instead homozygous for the most frequent one. Second, homozygous genotypes for the 
rarest allele (the reference) are never called.  
The pipeline relies on the creation of a variant sharing table, listing unique list of all the identified 
variants across the 17 exomes. For each variant, a sharing string was computed, composed by 17 
digit, corresponding to the 17 patients; for every patient, 0 indicated the absence of the variant, 1 
heterozygosity and 2 homozygosity for the variant. 
The variants listed in the table were then re-annotated using three different databases: dbSNP 
(release 142), 1000Genomes and ExAc; frequency annotations from IonReporter™ were ignored.  
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(http://www.ncbi.nlm.nih.gov/SNP/) is the reference database for known SNPs, collecting both 
common and rare polymorphisms. Any SNP reported in dbSNP has a relative reference sequence 
(rs) number. MAF to SNPs in dbSNP is provided by the 1000Genomes project 
(http://www.1000genomes.org/), currently including data from 2,504 human genomes. ExAc 
(http://exac.broadinstitute.org/) stands for Exome Aggregation consortium, collecting information 
relative to 60,706 exomes. 
Filtering was then performed on the basis of this information. Variants matching a dbSNP entry (in 
both position and alleles) were defined as SNPs and classified according to their frequency in 
1000Genomes as following: 
a. Common SNPs: MAF >=1% 
b. Rare SNPs: MAF <1% 
c. SNPs with unknown frequency 
d. mAiR SNPs: MAF >50%. 
The simultaneous analysis of the 17 exome data permitted the identification of mAiR cases. Since the 
non-reference allele is the most common one, infact, the probability that all the sequenced patients 
were homozygous for the reference was very low (This event occurring, the variant wouldn’t be of 
interest, as from the IBD map there is no haplotype shared by all the 17 patients). In the majority of 
the mAiR situations, therefore, the calling of the alternative allele generated an entry in the variant 
sharing table, recognized as mAiR after annotation and filtering. For these occurrences, real MAF 
was computed from 1000Genomes, by evaluating all the frequencies of alleles detected for the SNPs. 
Sharing string was then adjusted by replacing 0 with 2 and vice versa. In this way, homozygous 
reference calls were revealed. The corrected list of mAiR was then re-filtered according to the actual 
MAF, and variants with MAF <1% were retained. 
Rare SNPs, SNPs with unknown frequency and mAiR rare SNPs were further filtered by ExAc 
frequencies. Only variants not present or with a frequency <5% were preserved. The higher 
frequency threshold was determined both by the extremely higher sample size in ExAc and, 
especially, by the fact that psychiatric patients are included in ExAc collection. 
Any variant that was absent in dbSNP was placed in a separate list. From this group, variants 
detected in more than half (8) patients were excluded, since they were likely technical false positives. 
The remaining variants were filtered by ExAc frequencies similarly to rare SNPs. The resulting list 
was joined to the rare SNP one, to get the final subset of rare and novel variants. 
Finally, only variants mapping in IBD haplotypes were prioritized. It’s important to note that the IBD 
map was not simply a positional information, but it provided also insights on the sharing of a variant 
located in a specific haplotype. Both features were taken into account for prioritization.  
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3.9 Functional enrichment analyses 
Functional enrichment analysis was conducted exploiting the Database for Annotation, Visualization 
and Integrated Discovery (DAVID) tool (https://david.ncifcrf.gov/) (Huang et al., 2009a; Huang et al., 
2009b). A list of genes was compiled for each set of variants (all rare or novel, IBDtot, IBDsel, LoF, LoF 
IBDtot), including genes carrying at least one variant of the specified type. Lists were then tested for 
enrichment in one of the functional categories annotated by the Kyoto Encyclopedia of Genes and 
Genomes (KEGG, http://www.genome.jp/kegg/) and Reactome (http://www.reactome.org/). A 
significance threshold of 0.05 was established; multiple correction p-values were calculated with 
Benjamini method. Only results that were at least nominally significant (nominal p-value <0.05) were 
considered. Genes from interesting categories were mapped again on individual pathways/processes 
in the original KEGG and Reactome databases, to assess whether variants were evenly distributed or 
clustered in specific nodes.  
For a further dissection of the synaptic transmission category, enrichment analysis was performed on 
specific gene sets. PSD-95, ARC and NMDA receptor sets were derived from Fromer et al. (Fromer 
et al., 2014), who compiled the lists from proteomic studies. VGCC and glutamatergic synapse sets 
were instead assembled from KEGG annotation. Enrichment test was carried out considering an 
hypergeometric distribution; multiple test correction was again computed with Benjamini method.  
 
3.10 Analyses based on inference of variant sharing from IBD map 
Sharing and segregation of variants mapping in IBD haplotypes were inferred thanks to haplotype 
clusters. With this approach, the entire population sample could be investigated, starting from the 
data of the 17 exome-sequenced patients. 
Familial load of variants was calculated by simply adding the number of variants per family in genes 
belonging to the axon guidance or synaptic transmission processes, emerged from functional 
enrichment analysis. To complete the annotation from KEGG and Reactome, each category was 
expanded on the basis of Gene Ontology (GO) and DAVID functional classification; for axon 
guidance, ‘neuron development’ and ‘neuron projection’ terms were considered; terms like ‘synaptic 
transmission’, ‘synaptic plasticity’ and ‘synapse organization’ were instead acknowledged for synaptic 
transmission. Burden was then calculated for a total of 87 genes, with at least one novel or rare 
variant, in the axon guidance cluster, and 66 genes in the synaptic transmission one. 
Specific investigation of single variants were conducted on the basis of sharing results. In particular, 
prediction of effects for variants different from non-synonymous substitutions were obtained from 
MutationTaster (http://www.mutationtaster.org/) and Human Splicing Finder 
http://www.umd.be/HSF3/). All the cited variants have been validated by Sanger sequencing, after 
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amplification using a standard PCR protocol for FastStart Taq (Roche) (30 cycles at melting 
temperature of 60°) The complete list of primers can be found in appendix 7.6. The presence in both 
the exome-sequenced individuals and in the inferred cases was confirmed. 
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4. Results 
 
4.1 Copy Number Variant analysis 
In this study, a unique population sample has been deeply investigated for the search of rare risk 
factors conferring risk to schizophrenia (SCZ) and bipolar disorder (BPD) (see par 3.1). The working 
hypothesis is the likely enrichment of such rare alleles, on the basis of the high rate of endogamy and 
the increased prevalence of SCZ/BPD in this closed community. 
Copy Number Variants (CNVs) are amongst the first type of rare variants for which an implication with 
SCZ/BPD has been suggested. Thus the initial step of this work was the examination of CNVs in the 
population sample. A total of 165 individuals, of which 137 affected, were analyzed with the CNV-
webstore tool (Vandeweyer et al., 2011), for the calling and visualization of CNVs from SNP-
genotyping data. A total of 4827 duplications and deletions were detected, with an average of about 
30 variants per sample. 
These results were compared with a dataset of CNVs from one of the largest studies conducted on 
schizophrenic patients (Purcell et al., 2008). No overlap was found, indicating that none of the CNVs 
previously reported in SCZ patients was present in our sample. 
The focus then turned on the investigation of rare or novel CNVs in the 137 patients. An initial quality 
filtering was performed, selecting only larger (>30 kb) variants called with an average density of 1 
SNP every 10 kb. From the obtained 834 CNVs, a consensus was calculated across the samples. 
The consensus CNV loci were subsequently searched in the reference database of copy number 
polymorphisms (DGV, Database of Genomic Variants) and in the released data from the international 
HapMap project. A total of 61 rare (frequency <1%) or novel CNVs in 48 loci emerged. Surprisingly, 
none of the variants was neither perfectly segregating within a family nor shared by many affected 
subjects. Indeed, the majority of CNVs were singletons, thus present in a single subject. The most 
common novel CNV was a deletion in 8p22 (chr8:16,135,246-16,216,372 bp), detected in three 
subjects from families 85 and 110 (figure 4.1). No known SCZ/BPD locus map in that region (see 
table 1.1) and no gene resides in the deleted region, making it difficult to infer any pathogenetic 
hypothesis. These data thus indicated that CNVs likely play a minor role in the pathogenesis of 
SCZ/BPD in the analyzed sample.  
 
 
 
 
Figure 4.1: An 81 kb deletion (chr8: 16,135,246-16,216,372 bp) detected in two patients of family 110 and one in family 85. As 
shown, no gene is encompassed by this CNV. 
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4.2 The development of IBD mapping methodology 
4.2.1 Preliminary findings: linkage analysis 
The advantage of working with a collection of families, all with a common ancestry, is the possibility to 
identify risk variants by tracking loci shared by affected subjects. The classical approach for this 
purpose is linkage analysis, to identify loci that co-segregate with a disorder (see par 1.3.3.3). 
Genome-wide linkage scans with SNP markers had been previously performed on subsets of 
families, considering both parametric (dominant or recessive inheritance) and non-parametric models, 
but no significant results were achieved (see par 3.2 for details). Linkage approaches are likely 
ineffective when dealing with multiple risk factors rather than a single major gene, thus the preliminary 
findings suggest that also in this peculiar sample SCZ/BPD have a complex, polygenic inheritance. 
(Neale & Sklar, 2015). Moreover, even in the context of a reduced genetic complexity, intra-familial 
heterogeneity may hamper the detection of significant signals. A theoretical scenario to explain this 
issue is depicted in figure 4.2. In the hypothetic presence in the population of only three susceptibility 
alleles on different chromosomes, the transmission across generations could result in different 
combinations of such factors even in patients from the same family. Real risk alleles are probably 
more than three, but even this simplified example is sufficient to illustrate an expected genetic 
heterogeneity between patients. Additionally, a specific allele could be present also in non-affected 
subjects, given the typical incomplete penetrance of non-Mendelian variants. As a consequence, 
none of the factor would be perfectly co-segregating with the disorder within families and would 
produce statistically significant LOD score values. 
 
4.2.2. Identification of Identical-By-Descent (IBD) chromosomal segments 
In light of the failure of segregation-based studies, an original approach was designed, based on IBD 
(Identity By Descent) mapping. The rationale of this idea was that all patients belong to the same 
closed community, therefore risk alleles could have been reasonably located in founder haplotypes, 
passed through generations and found IBD in the modern population. (figure 4.2). IBD tracking was 
thus developed as a strategy to map these risk loci. One of the main strengths of the approach is the 
possibility to overcome segregation constrains, because the detection of IBD regions is conducted 
between all the existing combinations of analyzed individuals, pair by pair, without any a priori 
knowledge of familial relationships. 
Relate software (Albrechtsen et al., 2009) was selected among other available tools to perform IBD 
analysis from SNP-genotyping data. Parameters were accurately set up on sample subsets to get the 
most reliable results (see par 3.4). In particular, the algorithm was calibrated in order to remove SNPs 
in strong Linkage Disequilibrium (LD), a source of false positive results. Only SNPs with r2≤0.5 were 
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retained; after SNP pruning, analysis was carried out on 135,702 markers on the 22 autosomes, with 
an average of 1 SNP every 22 kb. Coherently, the average size of LD blocks in non-African 
populations is estimated around 22 kb (Cardon & Abecasis, 2003). Since Relate output files couldn’t 
be immediately interpreted, raw data were processed with a specifically developed pipeline based on 
PERL scripts. A total of 161,199 IBD regions were finally identified in the 19,306 pairs of 197 
individuals, ranging from about 50 kb to entire chromosomes, as between parents and children. The 
majority of segments were IBD1 (only one IBD homologue), but 2.9% of them were IBD2 (both IBD 
homologues); the detection of IBD2 sharing in pairs other than full- siblings was consistent with the 
presence of inbreeding in this population. It’s important to underline that IBD2 status doesn’t imply 
homozygosity, since also the sharing of the same two heterozygous haplotypes is possible. 
 
 
Figure 4.2: Theoretical scenario to explain intra-familial genetic heterogeneity. Here the presence of only 3 risk loci is 
hypothesized and the sharing across 3 families from the same population is simulated. Since the 3 loci map on different 
chromosomes, they segregate independently, thus patients from the same family may show different combinations of factors. 
Consequently, loci don’t co-segregate with the disorder and would unlikely produce significant linkage peaks. Considering the 
features of the investigated sample, however, these loci are probably located in founder haplotypes, that are therefore 
identical by descent (IBD). A strategy aiming at tracking IBD haplotypes could be thus effective for the identification of these 
risk factors. 
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4.3 Population studies from IBD data 
4.3.1 Genome-wide IBD sharing and biological relationships between subjects 
Since IBD analysis was a novel approach, completely set up in this work, the reliability of IBD data 
was initially evaluated. For this purpose, IBD regions were used to determine the portion of shared 
genome between each of the analyzed pair. This measure represents an estimate of the genetic 
similarity and should reflect the type of biological relationship existing between a specific pair of 
subjects. 
Shared genome was envisioned as the fraction of alleles that were IBD (r coefficient, or relatedness); 
genetic similarity was thus computed as the sum of the sizes of IBD1 regions and twice the sizes of 
IBD2 regions over the total genome size captured by the genotyped SNPs.  
 
𝑟 =
( 𝐼𝐵𝐷1 + 2 ∗ 𝐼𝐵𝐷2)
𝑡𝑜𝑡 𝑔𝑒𝑛𝑜𝑚𝑒
 
 
Calculated r coefficients are plotted in figure 4.3 and summarized in table 4.1; subject pairs were 
grouped according to their known relationships so that estimated values could be compared with the 
expected ones for each category. As shown, IBD data provided coherent results for all degrees of 
kinship. As an explicatory example, for parent-offspring pairs, who should share half of their genome, 
calculated r was on average 0.49954. Boxplots revealed also some outliers, that were further 
investigated. The majority of inconsistencies were obtained from an individual from family 4 (4_10); 
since none of the relationships with the other family members was correctly estimated, this sample 
had been probably misclassified. Other issues occurred with family 115 and were due to low quality 
genotyping data. Therefore, in addition to support the robustness of IBD analysis, this approach 
permitted the identification of some inaccurate data, information then considered in further analyses.  
Relationship category 
Expected r 
(relatedness) 
Calculated r 
(mean) 
N pairs 
Parent-offspring 0.50000 0.49954 54 
Full siblings 0.50000 0.49269 63 
Half siblings / Grandparent-
grandchild / Uncle-nephew 
0.25000 0.25303 34 
First cousins 0.12500 0.11234 14 
First cousins once removed 0.06250 0.06699 5 
Second cousins 0.03125 0.04261 1 
Unrelated 0.00000 0.00515 19,135 
Unrelated 
(independent population sample) 
0.00000 0.00069 528 
Table 4.1: Relatedness (r) of pairs of individual according to their biological relationships. Calculated 
values with IBD data were comparable with expected ones for all the degrees of kinship. 
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Since IBD regions could offer a reliable measure of genetic similarity in relatives, unrelated individuals 
were subsequently inspected. Interestingly, these pairs showed relatedness values considerably 
higher than expected, since basically no sharing was theoretically predictable. The average r was 
indeed significantly higher than the one computed in an independent sample of 33 individuals of 
Italian origin, analyzed with the same metrics (p<2.2E-16, Welch two-sample t-test) (figure 4.3). More 
in details, IBD estimates revealed that a great proportion of unrelated pairs are actually separated by 
no more than 4-5 generations (figure 4.4). From this evidence it was possible to conclude that this 
population sample has some characteristics similar to a genetic isolate, where the reduced migration 
fluxes and the assortative mating have led over time to an average increase of genetic relatedness. 
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Figure 4.3: Relatedness (r) 
calculated from IBD data. Pairs of 
subjects were categorized 
according to their degree of 
kinship. Expected values for each 
category are indicated by grey 
diamonds. For each degree of 
kinship, calculated values were 
coherent with the expected ones. 
Outliers were ascribable to: the 
pair of siblings in family 115 in 
full-siblings category; pairs 
including the subject 4_10  and 
her relatives in the other 
categories. Unrelated pairs from 
the investigated population show 
a relatedness significantly greater 
than the one between unrelated 
pairs of an independent Italian 
sample (p<2.2e-16).  
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Figure 4.4: Relatedness (r) of unrelated pairs. 
The number of generations between the 
members of a pair were estimated according to 
their r. This computation revealed that more 
than 50% of pairs were separated by 4-5 
generations.  
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4.3.2 Cluster analysis 
After the emerging of genetic links between theoretically unrelated individuals, a connected question 
was whether the sample was homogeneous or if some of the families were more related than others. 
To address this issue, a member of each family branch was selected, defining a subset of 115 ‘family 
founders’. On the basis of estimated genetic similarity (r), specific analyses were performed to identify 
eventual population subgroups 
Multidimensional scaling revealed the unexpected presence of two main clusters of ‘family founders’ 
(figure 4.5). Remarkably, in-depth examination of registry data suggested that the clusters roughly 
corresponded to the local origin of individuals. In fact, samples were collected from two main close 
areas (figure 3.1), named Chioggia (the main town) and Sottomarina (its neighborhood), referring to 
the same Mental Health Center.  
  
 
Figure 4.5: Multidimensional scaling of genetic distances (1-r) in 115 ‘family founders’. Two main clusters of subjects appeared, 
broadly corresponding to the local origin from Chioggia (blue) or Sottomarina (red). Unknown origins are shown in grey. The 
three individuals on the top right area of the panel were identified as 79_5, 53 and 71, who are particularly highly related, thus 
placed in an independent cluster, corresponding to the one indicated with ‡ in the dendrogram below (figure 4.6). 
To get more insights, 53 unrelated individuals were further added to the original subset: beyond the 
33 samples of Italian origin previously cited, 20 samples were retrieved from the HapMap project, 5 
for each main available ancestries, Yoruba (Africa), Han Chinese in Beijing (China, Asia), Japanese 
in Tokyo (Japan, Asia) and Europeans in Utah (Europe). HapMap samples were processed as 
already described to obtain genetic similarities. Hierarchical clustering of the total 168 individuals is 
represented by the dendrogram in figure 4.6. As evident, samples were correctly grouped according 
to their ancestry. Again, the 115 family founders from the studied population were split in two main 
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branches, which significantly matched their local origin (p=2.12 e-8). Within the Sottomarina cluster, 
dendrogram displayed 2 sub-clusters, composed by 2 (¥ in the figure) and 3 (‡ in the figure) 
individuals respectively. These subjects didn’t show an increased genetic distance from the other 
members, rather a very high relatedness among them. Therefore the separation results from the 
attempt of the algorithm to accommodate this elevated genetic similarity. About the Chioggia cluster, 
then, the majority of samples clustered to a branch distinct from the Italian/European subjects; 
although this might reflects the likely genetic isolation, the difference was not significant. 
Concluding, the investigated population can be viewed as composed by two extended pedigrees, 
each constituted of smaller familiar nuclei connected by substantial genetic links. Considering the 
high significance of the analysis, clusters were used to infer the belonging to Chioggia or Sottomarina 
sub-group for the 24 family founders with uncertain origin. Discordances between the predicted origin 
and the referred information were carefully re-evaluated by checking familial registers and some data 
were corrected (appendix 7.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6 (on the opposite page): Dendrogram of genetic distances calculated from IBD data in 168 subjects (115 ‘family 
founders’ and additional unrelated 53 individuals from independent populations). Samples were clustered according to their 
ancestry (African, Asian and European). Moreover, Chioggia and Sottomarina were significantly distinguished (p=2.12 e-8, 
linear model with origin as co-variate). The two sub-cluster of particularly related individuals are indicated by the ‡ and ¥ 
symbols (see main text for details). Individuals from Chioggia were grouped separately from the European/Italian ones, 
indicating a likely genetic isolation, although the difference was not significant. 
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4.4. IBD mapping: tracking haplotypes shared by patients 
Considering the population features of a genetic isolate, combined with the high prevalence of 
SCZ/BPD, IBD mapping was sought as a strategy to track susceptibility loci for these complex 
disorders. The foundation of the approach was the identification of clusters of individuals with 
identical haplotypes, starting from the list of IBD regions obtained from pairwise IBD analysis. This 
couldn’t be achieved by simply grouping all pairs with IBD segments encompassing the same specific 
position, since the existence of two homologous chromosomes had to be taken into account. An 
explicative example is represented in figure 4.7 As shown, if the same region had been found IBD in 
three pairs of three individuals, this wouldn’t necessarily imply that all of them share an identical 
haplotype; an individual, in fact, could share a different haplotype with each of the other two subjects 
(figure 4.7a). A simplistic interpretation of IBD data could thus lead to erroneous conclusions. The 
problem could be overcome thanks to a logical rule: whenever the same region was IBD in all 
possible pairs of at least 4 individuals, an identical haplotype shared by all the subjects had to be 
assumed (figure 4.7b) (Thompson, 2013). This was then the minimum requirement for building a 
cluster (figure 4.7c). 
 
 
Figure 4.7: Resolution of haplotype clusters from pairwise IBD data. If the same region is IBD in all the three pairs of 3 subjects 
(A,B and C), resolution of the cluster is not unique (panel a). Thus the assumption of a common haplotype may be incorrect. 
Conversely, if the same situation occurs for the 6 pairs of 4 individuals (A,B,C, and D), then the resolution have a unique 
outcome, implying a shared haplotype for all the subjects (panel b).  This was therefore the basis for the building of clusters 
and a further individual (E in the example) was added whenever it displayed IBD in the same region with all the other members 
of the cluster (panel c).   
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Haplotype clustering was performed systematically, exploiting a sliding window of 200 markers. The 
entire genome was scanned and clusters were built position by position, considering pairwise IBD 
segments overlapping the window. Consensus clusters were then calculated to finally obtain a 
complete, genome-wide map of IBD shared haplotypes, with relative chromosomal coordinates and a 
list of subjects carrying the specific alleles. 
 
From the examination of IBD map, important observations emerged. First, a subset of individuals (6 
cases from 3 families, 8 single or isolated cases and 1 control) could never be included in any 
haplotype cluster. Notably, in the previously described dendrogram these subjects were grouped in 
the sub-branch identified by Italians and Europeans (figure 4.6). This evidence indicated that these 
individuals were unlikely belonging to the population sample under investigation (appendix 7.3). 
Second, identical haplotypes could be tracked across multiple families, revealing a puzzle of shared 
segments in different chromosomes (figure 4.8). 24% of haplotypes were restricted to a single family, 
44% encompassed 2 families, while 32% were shared across 3 or more pedigrees. Interestingly,  
20% of them were specifically present in patients with SCZ, while 5% were exclusive of BPD subjects 
(figure 4.8c,d). The majority of haplotypes, however, crossed diagnostic boundaries. Surprisingly, 
haplotype sharing didn’t reflect the population stratification highlighted by the cluster analysis. A 
consistent number of regions, in fact, were common to families both from Chioggia and Sottomarina, 
suggesting some level of admixture between the two subgroups. As a last remark, particular 
combinations of haplotypes on different chromosomes could be found co-segregating within and 
between families. This evidence was especially relevant because it could point to possible interplays 
of genetic factors contributing to risk. 
 
IBD map thus provided a valuable tool to dissect genomic sharing both at familial and at population 
level. With the aim of focusing on IBD haplotypes mostly relevant to the disorders, a prioritization was 
performed by selecting from the total IBD map (IBDtot) the haplotypes encompassing more than two 
pedigrees and shared by at least half of the patients within each nucleus (IBDsel). 648 overlapping 
haplotypes emerged from this step, with a size between 3 and 67 Mb. 
These haplotypes are the most shared within and between families and under the original hypothesis 
they could carry susceptibility alleles with strong effect on disease liability.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8: sharing and segregation of haplotypes determined with IBD map. Some interesting examples of loci shared across 
different families are reported. Panel a show a haplotype specific for the Sottomarina sub-group; conversely, the haplotype in 
panel b was shared by samples from the two population clusters (family 79 from Sottomarina, family 9 from Chioggia). Some 
phenotype specificities also emerged. Panel c represents a haplotype co-segregating with SCZ, while an panel d illustrates an 
analogous situation for BPD. Finally, a combination of haplotypes on two different chromosomes is depicted in panel e.  SCZ: 
schizophrenia; BPD: bipolar disorder; SZA: schizoaffective disorder; NS: not specified, referred affected with SCZ or BPD. 
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4.5 Whole-exome sequencing 
4.5.1 Variant annotation and filtering 
For the detection of rare variants possibly implicated in SCZ/BPD, whole-exome sequencing (WES) 
was performed on 17 patients; analyzed subjects were selected on the basis of IBD map, in order to 
cover the most interesting IBD haplotypes: with this approach, 75% of IBDsel haplotypes were 
theoretically analyzable. Next-generation sequencing was carried out with IonTorrent™ technology 
(Life Technologies). 
Annotation of variants was initially achieved with IonReporter™, the standard software for 
IonTorrent™ data processing. In a second step, variant frequencies in reference databases were re-
annotated exploiting a specifically developed pipeline. This strategy was adopted to overcome some 
issues encountered with the use of IonReporter™, leading to a consistent loss of variants during 
frequency filtering. Among the most relevant ones is the annotation of variants as known 
polymorphisms (SNPs) by considering only the genomic position, without any allele check. Another 
problem derives from inaccuracies in the reference human genome (GRCh37/hg19 assembly); for 
some SNPs, the reported reference allele doesn’t correspond to the most frequent one in the general 
population (mAiR, minor Allele in Reference). As a consequence, common alleles are typically called 
as variants, while homozygous genotypes for rare alleles are not detected (see par. 3.8 further 
details). 
The developed pipeline is based on the creation of a variant sharing table, listing all the identified and 
annotated variants across the 17 exomes, with their relative presence in the sequenced patients. The 
simultaneous evaluation of all the exome data allowed the detection of mAiR situations, thus the 
proper classification of rare alleles. Frequency of variants was checked in three different databases: 
dbSNP, 1000Genomes and ExAc. Rare variants were defined as those reported in dbSNP, with a 
MAF<1% in 1000Genomes database and absent or with a frequency <5% in ExAc. Novel variants 
were instead those not present in dbSNP. Another advantage of working with the variant sharing 
table was the possibility to immediately prioritize variants according to IBD map. In subsequent steps, 
two narrower classes of rare or novel variants were specified, the ones mapping in any of the IBD 
haplotypes (IBDtot) and the ones in selected IBD haplotypes (IBDsel). 
 
Of the 138,725 variants identified in the 17 patients, 17,385 were rare and 12,832 novel, for a total of 
30,217. All the following investigations were conducted starting from this subset. Remarkably, 4.5% of 
these selected variants corresponded to mAiR situations. Further, 6,621 variants mapped in IBDtot 
haplotypes and 558 in IBDsel ones. Interestingly, in all of these categories, the majority of variants 
were non coding, in line with what reported in other studies, both on common and rare variation 
(Ament et al., 2015; Ripke et al., 2014) (figure 4.9). Additionally, variant distribution in relation to the 
effect showed no substantial changes in the different filtering processes; for example, missense 
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variants represented always about 20% of the total. This indicates that any of the variant types was 
preferentially more shared in patients. Among the coding variants, a supplementary category was 
defined, including novel and rare variants with a likely damaging effect (frameshift insertion/deletions, 
splicing alterations, nonsense, stoploss and missense predicted deleterious by CONDEL software), 
generally named loss of function (LoF). Also this subset was mapped into IBDtot and IBDsel 
haplotypes. 
 
 
Figure 4.9: Effect of the variants progressively prioritized for frequency (MAF<1% or novel) (a), IBDtot halpotypes (b) and IBDsel 
haplotypes (c). As shown, the proportion of variants in the different effect categories was almost unchanged across the 
prioritization process, suggesting that any of the variant type was particularly more shared in patients. Additionally, non coding 
variants were always predominant, indicating their possible role in etiology of SCZ/BPD. 
 
4.5.2 Functional enrichment analysis 
Functional enrichment analysis aimed at determining whether prioritized variants were specifically 
affecting any biological process. DAVID online tool (Huang et al., 2009a; Huang et al., 2009b) was 
exploited for this purpose, focusing on KEGG and Reactome functional gene annotations. The 
previously defined categories of rare or novel variants were tested. As reported in table 4.2, two main 
processes consistently emerged across all the subsets of IBD variants: axon guidance and synaptic 
transmission; even more, axon guidance as annotated by Reactome and synaptic transmission 
showed significance after multiple-test correction in IBDtot (see appendix 7.4 for complete results). 
Remarkably, both of these processes have been described as possibly relevant for SCZ/BPD (see 
par 1.4). Four more pathways were repeatedly found and inspected because possibly related to the 
previous functions: PIP signalling, signalling by rho GTPases, ECM-receptor interactions and cell 
adhesion molecules. These are in fact basic cellular cascades intervening in a variety of biological 
processes. Cell-cell and cell-matrix interactions are particularly involved in axon guidance, as 
fundamental for neuron projection and connectivity during development. Similarly, 
phosphatidylinositol and rho-GTPase signalling are active in postsynaptic signal transduction. Thus 
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these outcomes suggest a broad convergence again on axon guidance and synaptic transmission 
functions, as sustained by the overlap between genes in these latter categories and in the four 
singalling cascades in the analyzed dataset. 
IBDsel set of variants showed no significant enrichment for any pathway reported in DAVID. These 
results could either simply reflect the considerably lower number of genes tested, or they could also 
indicate that many of the variants in these functional categories are not largely shared by patients. It’s 
however notable that almost all the nominally significant pathways in this analysis were those already 
described, ascribable to axon guidance and synaptic transmission. Instead, the lack of enrichment in 
LoF categories, even after IBDtot mapping, suggests that the significant outcome in IBDtot genes was 
not driven by coding variants with predicted damaging effects. 
Functional 
annotation class 
p-value (adjusted p-value) 
all IBDtot IBDsel LoF LoF IBDtot 
Synaptic 
transmission 
(Reactome) 
2.93E-04 
(2.06E-02) 
6.02E-03 
(9.75E-02) 
3.87E-02 
(3.61E-01) 
NS NS 
Axon guidance 
(Reactome) 
1.30E-03 
(3.03E-02) 
3.82E-05 
(1.30E-03) 
2.60E-02 
(5.91E-01) 
2.32E-02 
(5.5E-01) 
3.77E-02 
(8.64E-01) 
Axon guidance 
(KEGG) 
6.68E-04 
(1.88E-02) 
3.72E-02 
(4.14E-01) 
1.63E-02 
(8.87E-01) 
4.97E-02 
(5.35E-01) 
NS 
PIP signalling 
2.31E-04 
(9.13E-03) 
5.64E-03 
(1.20E-01) 
2.45E-02 
(8.06E-01) 
2.35E-02 
(3.71E-01) 
NS 
Signaling by rho 
GTPases 
5.48E-04 
(1.93E-02) 
2.79E-05 
(1.89E-03) 
NS 
2.77E-02 
(3.80E-01) 
7.80E-03 
(3.34E-01) 
ECM-rec. 
interactions 
(KEGG) 
3.42E-05 
(3.40E-03) 
2.59E-07 
(5.11E-05) 
NS 
5.68E-07 
(1.11E-04) 
9.11E-04 
(1.44E-01) 
Cell Adhesion 
molecules (KEGG) 
NS NS 
4.75E-02 
(8.82E-01) 
3.22E-02 
(4.13E-01) 
4.22E-02 
(5.59E-01) 
 
Both axon guidance and synaptic transmission are large and general categories including several 
genes and functions. For this reason, a more detailed investigation was envisioned. Many signalling 
pathways are annotated as part of axon guidance both in KEGG and in Reactome. However, rare or 
novel variants mapping in IBD haplotypes (IBDtot and IBDsel) were affecting almost exclusively NCAN 
signaling for neurite outgrowth. Even more, genes carrying these variants were located in specific 
nodes of the pathway (figure 4.10). For example, as highlighted in figure 4.10b, neural cell adhesion  
Table 4.2 Summary of functional enrichment analyses for different categories of prioritized variants, For each category, a list of 
genes was compiled, including those genes carrying at least one variant of the specified type. Only annotation classes that 
were at least nominally significant were considered and the most consistent results are here reported. For multiple testing 
correction, Benjamini method was selected and significant outcomes are highlighted in bold. 
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molecule 1, encoded by NCAM1, interacts with several other proteins for the development of neuron 
projection, such as neurocan (NCAN), collagens and glial cell derived neurotrophic factor (GDNF); 
novel or rare variants in IBD haplotypes were detected in all of these cited genes. 
 
 
 
 
 
Figure 4.10: NCAM singnalling for neurite outgrowth pathway, a sub-process of axon guidance, according to Reactome 
annotation. Rare or novel variants mapping in IBD haplotypes were specifically affecting portions of this pathway, as 
highlighted by panels a and b. Genes carrying at least one variant are marked with a red star. Several of these genes were 
direct interactors, as NCAM1 and FGFR1, or NCAM1 and NCAN (panel b). 
Analogously, synaptic transmission is a broad category that includes all types of presynaptic, synaptic 
and postsynaptic mechanisms concerning neurotransmitter release and actions. Nevertheless, 
numerous IBDtot and IBDsel variants were in genes involved in glutamatergic synapse functions, as the 
glutamate metabotropic receptors GRM7 and GRM8 or the NMDA ionotropic receptors GRIN2A 
andGRIN2B. 
a 
b 
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4.5.3 Gene-set enrichment analysis 
To further dissect these observations, a collection of gene sets were retrieved from the studies of 
Fromer et al. and Kirov et al. (Fromer et al., 2014; G Kirov et al., 2012). These gene sets were 
assembled from proteomic data analyzing the full collection of interactors of specific postsynaptic 
complexes intervening in NMDA signalling, such as ARC (activity-regulated cytoskeleton-associated 
scaffold protein), PSD-95 (post-synaptic density protein-95) and NMDA receptors themselves. 
Additionally, two more sets, glutamatergic synapse and VGCCs (voltage-gated calcium channels), the 
latter composed by synaptic channels mediating Ca2+ influx upon membrane depolarization, were 
manually assembled from KEGG annotations. 
As shown in table 4.3, the previously implicated ARC and PSD-95 complexes were significantly 
enriched in genes affected by all categories of variants tested. Coherently, NMDA receptor and 
glutamatergic synapse gene sets evidenced the same outcome. Therefore, the prioritized variants 
based on the IBD sharing, including IBDsel haplotypes, were selectively clustering in genes involved in 
glutamatergic synapse transmission, particularly in postsynaptic mechanisms mediated by NMDA 
receptors. The VGCC gene set, however, still showed a significant enrichment only in IBDtot variants, 
indicating again a possible more private distribution of these alleles across families. 
Taken together, these results indicate a load of rare or novel variants affecting specific portion of 
axon guidance and glutamatergic synapse processes in SCZ/BPD patients. 
Gene set  
(n genes) 
p-value (adjusted p-value) 
all IBDtot IBDsel 
Glutamate synapse 
(92) 
3.13E-10 
(1.88E-09) 
1.70E-06 
(5.10E-06) 
3.28E-03 
(6.68E-03) 
NMDA receptors  
(61) 
9.48E-09 
(2.84E-08) 
7.80E-05 
(1.18E-04) 
9.12E-03 
(1.37E-02) 
ARC 
(28) 
4.20E-02 
(4.20E-02) 
2.41E-05 
(4.82E-05) 
2.05E-02 
(2.46E-02) 
PSD-95 
(117) 
1.15E-03 
(1.38E-03) 
2.41E-03 
(2.41E-03) 
3.34E-03 
(6.68E-03) 
VGCC 
(26) 
9.07E-07 
(1.36E-06) 
9.29E-04 
(1.11E-03) 
1.03E-01 
(1.03E-01) 
Table 4.3: Gene-set enrichment for genes carrying at least one novel or rare variant in IBDtot or IBDsel haplotypes. 5 gene sets 
were tested considering a hypergeometric distribution. Adjusted p-values were calculated with Benjamini method. Significant 
outcomes are highlighted in bold. 
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4.5.3 Recurrence of functionally related variants in families 
One of the main advantages of the IBD map was the opportunity to infer the sharing and the 
segregation in non sequenced individuals of any variant located in IBD haplotypes. On the basis of 
this feature, the entire sample was investigated at a family and population level. 
A global overview of single families revealed that each nucleus carried multiple variants in the axon 
guidance and synaptic transmission pathways (figure 4.11). Since many of the genes with variants 
were not annotated in KEGG or Reactome, the original sets were expanded with functionally related 
categories form DAVID or Gene Ontology, for a total of 87 genes in the axon guidance cluster and 66 
genes in the synaptic transmission one. The recurrence of functionally related variants in a family is 
compatible with a polygenic nature of the disorders, where multiple risk factors contribute to risk. 
Interestingly, the 13 controls showed in general a lower amount of such variants. This was unlikely 
attributable merely to the fact that families included several subjects, since the selected variants were 
mapping in shared IBD haplotypes, reducing the possibility that each family member contributed with 
different variants independently. Indeed, the higher loads were not observed in the largest families. 
 
 
Figure 4.11: Burden of rare or novel variants involved in axon guidance (red) or synaptic transmission (blue) in families. The 
proportion of variants in the two functional categories is different in the families, indicating a certain heterogeneity. 
Interestingly, controls seem to have a lower load of these mutations. 
 
At the same time, data evidenced some genetic heterogeneity between different families, with 
variable loads of variants on the two considered functional processes. For example, family 3 and 9 
have a higher proportion of rare or novel alleles affecting synaptic transmission, while the opposite 
situation can be outlined for families 84 and 85. 
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To get more insights on variants individually, a further investigation was performed. Detailed 
information about all the analyzed variants can be found in appendix 7.5 The single variant 
examination revealed that some of the alleles in functionally related genes were co-segregating in the 
same pedigree, even if mapping on different chromosomes. Some illustrative results are reported in 
figure 4.12. As shown, patients from family 85 carry two variants in NCAN and NCAM1 genes, 
involved neurite outgrowth, as described above (figure 4.10). Analogously, two variants in two 
metabotropic glutamate receptors (GRM7 and GRM8 genes) perfectly co-segregate with the disease 
in family 62. 
 
Figure 4.12: Burden of functionally related variants in families. In family 85 an intronic variant in NCAM1 was co-segregating 
with a missense substitution in NCAN. These genes encode for proteins which directly interact in the neurite outgrowth 
process. In family 62, two synonymous variants in the glutamate metabotrobic receptors GRM7 and GRM8 were detected in all 
the patients. 
 
 
 
It is noteworthy that some of these variants, especially the ones in IBDsel haplotypes, where shared in 
different pedigrees. A typical scenario is represented in table 4.4 and figure 4.13 for a subset of 
families. In the proposed example, a variant in CACNA1E gene, a VGCC, is present in family 9 and in 
one of the two patient of family 111. In family 111, a second variant in the FNBP1L gene, involved in 
Ca2+ mediated synaptic plasticity, is shared by both the patients and additionally co-segregates with 
SCZ in family 15. Interestingly, in this latter family, also a variant in the DLG4 gene is passed from the 
affected mother to all the three affected sons; Dlg4, also known as PSD-95, is a key protein in 
postsynaptic modulation of NMDA receptors and related plasticity. Similar considerations can be 
outlined for the other shown variants as well. 
 
58 
 
gene functional category  
families 
9 111 15 24 78 additional inds 
CACNA1E synaptic transmission           17_1;23_4 
FNBP1L synaptic transmission           47_1;90_2 
DLG4 synaptic transmission           4_1;64_1 
FGFR1 axon guidance           90_2 
NLGN1 axon guidance           fam7;21_2;47_2 
 
 
Table 4.4 and Figure 4.13: A schematic representation of the complex puzzle of loci emerging from sharing analysis of 
variants. The sharing of variants in some of the candidate genes is shown in the table for a subset of families . Each of the 
variants has a different sharing pattern, encompassing different pedigree. The result is a polygenic load of functionally related 
alleles in each family. A detailed view of the sharing of three variants is depicted in the figure underneath. Although some of the 
candidate risk alleles show a perfect co-segregation with the disorders (e.g. FNBP1L, DLG4), some others show incomplete 
penetrance, or are not shared by all the patients of a family (e.g. CACNA1E); this suggests again the absence of a major gene 
and instead the presence of an intra-familial heterogeneity, as initially hypothesized, and  typical of complex disorders.  
 
 
Another relevant observation emerging from the sharing analysis was the presence of multiple 
haplotypes encompassing the same locus, but associated with different variants. For example, in the 
DLG4 gene two variants were detected, mapping in just as many haplotypes, shared across distinct 
groups of families (appendix 7.5). The same situation was identified for the NLGN1 gene. The 
evidence that different rare or novel variants on the same genes were shared by patients strongly 
support the involvement of DLG4 and NLGN1 in the etiology of the disorders.   
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As a final remark, sets of variants could be found co-segregating not only within a family, but in 
different pedigrees. This led to the hypothesis that risk could be substantially increased by specific 
combinations of a few functionally related alleles. The most remarkable results were observed for 
variants in ARHGAP32 and CDH13, two genes acting on the development of neuronal projections 
through cell adhesion and cytoskeleton remodelling. These two variants, mapping on chromosomes 
11 and 16 respectively, were found together in 5 patients from families 19 and 20 (figure 4.14). Other 
combinations were detected, although with a more limited sharing in patients from the same families. 
For example, CACNA1E and PRKCB rare alleles were both presents in families 9 and 78. PRKCB is 
a protein kinase active in postsynaptic neurons upon Ca2+ signaling, that is mediated by VGCCs. 
Analogously, the CNTN2 and SEMA3C genes are both playing a role in axon guidance. A rare 
missense variant with a loss of function prediction was found in each gene; the combination of these 
two variants was detected in cases of families 40 and 85. Further investigations in this sense will be 
required to confirm this fascinating theory. 
 
 
Figure 4.14: Combinations of variants detected in several patients of different pedigrees. Here is shown the example of two 
missense substitutions in the ARHGAP32 and CHD13 genes. The combination is perfectly segregating in family 19 and is 
further detected in the two bothers from family 20. Both these genes are involved in the formation of neuron projection, thus the 
simultaneous presence of susceptibility variants could substantially increase the risk of developing SCZ.  
 
 
Concluding, these analyses overall highlighted a puzzle of different variants, each with a proper 
sharing pattern across families, resulting in a burden of functionally related rare alleles in a specific 
pedigree. 
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5.  Discussion and conclusions 
 
5.1 The development of a novel approach combining IBD mapping 
and whole-exome sequencing 
Schizophrenia (SCZ) and bipolar disorder (BPD) are among the top 20 causes of disability worldwide 
(WHO). Despite this, their etiology is still largely unknown and generally poor outcomes are 
associated with both the disorders. In fact, available drugs are only partially effective and associated 
with strong side-effects. The understanding their genetic architecture results therefore extremely 
important, with the aim of developing more successful treatments. Recently, an involvement of rare 
variants has been repeatedly proposed (Kerner, 2015; Lee et al., 2012; Neale & Sklar, 2015), but 
their investigation in large case-control cohorts have produced limited results (Fromer et al., 2014; 
Purcell et al., 2014). In this work, a different type of sample is analyzed, composed by 36 families with 
high recurrence of SCZ and BPD and 55 additional cases. The peculiarity of the sample is that all 
individuals have a common ancestry from a small town in the Venetian lagoon, considered a closed 
community for cultural reasons. The singular high number of SCZ and BPD cases, and specifically of 
familial cases, offers a unique opportunity to investigate the genetic architecture of these two 
disorders, as the homogenous background suggests an enrichment of rare risk alleles. Indeed, a 
higher prevalence of some rare pathogenic alleles has been reported in this population, such as the 
Factor V Leiden, a risk factor for venous thrombosis, (Gessoni et al., 2010) and a DSC2 (desmocollin 
2) mutation causing arrhythmogenic cardiomyopathy (Lorenzon et al., 2015). The latter was also 
shown to map in a shared founder haplotype. 
 
Copy number variants (CNVs) have been the first type of rare variants implicated with the disorders, 
especially with SCZ. For this reason, a CNV analysis was initially performed on the population 
sample. No previously reported SCZ/BPD structural variant was detected, thus rare and novel CNVs 
were searched. However, the limited sharing of the identified variants suggests that CNVs are 
unlikely to play a major role in this sample. Nevertheless, the possibility that some of the variants 
partially contribute to the disorder can’t be completely ruled out. Additionally, the method employed 
for the calling of CNVs has poor performances with small structural variants, so that a threshold of 
30kb size was imposed. Further detailed analyses are thus required to get more insights on these 
variants. 
 
In the light of these findings , a novel and alternative approach was envisioned, exploiting one of the 
main advantages of familial-based population samples: the possibility to track loci segregating with 
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the disorders within a pedigree and shared across patients from different nuclei. The approach 
combines IBD mapping and whole-exome sequencing (WES) for the identification of rare sequence 
variants that may contribute to genetic risk for the disorders. Recent studies have actually 
demonstrated the effectiveness of combining a mapping strategy with next generation sequencing in 
families. Even though linkage analyses have been largely preferred in pedigrees, IBD has been 
sometimes more successful in uncovering mutations, particularly with rare recessive Mendelian 
disorders in consanguineous families. This was the case for retinal dystrophy (Coppieters et al., 
2014) and non-syndromic intellectual disability (Mir et al., 2014), where the search of homozygous 
IBD2 haplotypes, also known as homozygosity mapping, was used to prioritize exome variants. IBD 
haplotypes have also proven to be even more efficient than linkage in restricting candidate loci when 
analyzing multiple families with familial late-onset Alzheimer’s disease (Kunkle et al., 2016). Linkage 
analysis can be seen as a particular form of IBD mapping, that tracks haplotypes specifically 
segregating with a trait within families. For this reason, it has a reduced power when dealing with 
complex disorders, due to the genetic heterogeneity and the incomplete penetrance that characterize 
risk alleles, in contrast with Mendelian mutations (Neale & Sklar, 2015). Additionally,  the eventuality 
of phenocopies must be taken into account for common disorders. IBD mapping has been already 
proposed as an alternative strategy to dissect the contribution of different haplotypes when multiple 
risk factors are involved (Marchani & Wijsman, 2011). In the present work, IBD mapping is applied for 
the first time in a systematical fashion, as a tool for the identification of loci shared by SCZ and BPD 
patients.  
 
 
5.2 Technical considerations about the IBD analysis 
IBD analysis was completely designed in this study, starting from genome-wide IBD predictions 
obtained with Relate software. Several considerations have been made before the selection of the 
proper tool for IBD detection. Hidden Markov Model-based algorithms are notoriously heavy from the 
computational point of view, and numerous days were required to run Relate on the 197 samples. 
Despite, it was retained the most suitable method for the type of sample analyzed. Alternative 
algorithms, in fact, rely on the identification of identical segments of markers, then determining if the 
observed haplotype is IBD rather than IBS on the basis of frequency in the sample (BEAGLE fastIBD) 
(Browning & Browning, 2011) or length (GERMLINE) (Gusev et al., 2009). The lower the frequency 
and the greater the size, the lower the probability that the haplotype occurs multiple times 
independently, thus a common inheritance is assumed (Browning & Browning, 2012). However, in a 
closed population with a recent ancestry, haplotypes might have been quite common and extended, 
particularly considering the high number of familial cases and the multiple degrees of kinship existing. 
Indeed, the majority of methods are developed to track IBD among distant relatives. GERMLINE was 
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specifically tested on this purpose, but poor outcomes were achieved, especially in the initial step of 
data phasing, based once again on haplotype frequencies. The main strength of Relate, instead, is 
provided by the preliminary SNP pruning from LD, that is calibrated on the input sample, avoiding 
biases from genetically distinct populations. The simultaneous analysis of the two Chioggia and 
Sottomarina clusters on one hand make it possible to use a sufficient number of sample to get a 
realistic estimation of LD profiles; on the other hand, the presence of two sub-populations avoided 
excessive pruning due to the extreme homogeneity. In the phase of haplotype clustering, then, IBD 
regions shorter than 100 SNPs, more likely to be false positive calls, were automatically excluded 
from the analysis. Eventual false negative occurrences were then adjusted in the consensus process, 
when very similar clusters of individual were merged; clusters in the same position, but differing only 
of one of two individuals, in fact, were likely the result of a missing call for an IBD region between a 
pair, that was interrupting the cluster building. The random order of extension, repeated multiple 
times, granted the production of differentially discontinued clusters, highlighting these situations and 
allowing their resolution. 
 
5.3 Population genetics studies using IBD data 
The efficacy of the probabilistic method employed by Relate was revealed by the correct estimation of 
genetic similarities among pairs of individuals, according to the degree of kinship. The software could 
thus uncover IBD segments even in the presence of a net of biological relationships. In unrelated 
pairs, a particularly high relatedness emerged, providing a genetic evidence of the population 
isolation and inbreeding. Before these findings, these features has been reasonably assumed on the 
basis of historical data. The town, in fact, was completely destroyed in 1380, during the war 
counterposing Venice and Genoa. In the following centuries, the population was repeatedly 
decimated by pestilences and famines and only in the most recent times an exponential growth 
occurred, accompanied, however, by reduced migration fluxes. Therefore, both genetic and historical 
information converge in stating that the ancient community in Chioggia has some characteristics of a 
population isolate. As a further indication, three surnames account for about 50% of inhabitants 
(Gessoni et al., 2010). Chioggia was also recognized as the town with the highest rate of isonymy in 
Italy, again stressing the low migration and the endogamy that characterize this area (Barrai et al., 
1999). 
 
A further inspection of familial connections within the sample revealed the presence of two main sub-
populations, corresponding to two close geographical areas: Chioggia and Sottomarina. Sottomarina 
is politically a neighborhood of Chioggia, the major town, which is located on a different island 1.5 km 
apart, connected through a bridge. Despite the proximity, however, the two populations have been 
maintained historically separated for cultural reasons: Chioggia inhabitants were predominantly 
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fishermen, while Sottomarina was devoted to agriculture. Although these areas are today popular 
seaside resorts, ancient residents may still reflect the marked partition. Noteworthy, this sample 
stratification didn’t appear after the construction of the IBD map. The results are not in conflict with 
each other, as the two approaches highlight different aspects of genome sharing. In the population 
analysis  any type of pairwise IBD region was considered, while haplotype clustering requires that the 
same region had to be detected in at least four individuals. A relevant implication from these results is 
therefore that the overall IBD sharing reflects the genetic differences between the two subgroups, 
while the IBD map highlights the mostly shared haplotypes in patients and these latter are common in 
part to Chioggia and Sottomarina. This admixture would coherently explain the high prevalence of 
SCZ/BPD in both the areas, due to a common genetic background. Otherwise, environmental factors 
should be considered as major determinants, but this would be in contrast both with the known 
heritability of the disorders and with the familial aggregation observed in the sample. 
For the enunciated reasons, beside the outcomes from the cluster analysis, Chioggia and 
Sottomarina subgroups were examined together in the search of rare risk alleles.  
 
5.4 Filtering of whole-exome sequencing data with IBD map 
IBD map was created with the intent to realize a valuable instrument to understand the pattern of 
sharing and segregation of any genomic locus in the analyzed population. Thanks to the haplotype 
clustering approach, in fact, far more informative data were obtained compared to the mere IBD 
output, that provided only pairwise knowledge. As already cited, the map offered the advantage to be 
free from segregation constrains and offered the possibility to track loci across families. The 
integration with exome-sequencing data, then, permitted first to strongly prioritize variants and, 
second, to investigate the entire population from the data of 17 patients, inferring the occurrence of 
variants in the non-sequenced samples. 
 
Both IBD mapping and exome data processing were realized with in-house pipelines, developed to 
accomplish specific tasks and overcome some issues emerged with standard variant filtering. In 
particular, the annotation of variant frequency information was especially curated. The correct 
identification of novel variants was ensured by the match not only of position but also of the reported 
alleles. Precise filtering was then obtained by checking which of the reported alleles for a 
polymorphism was actually the less frequent, resolving inaccuracies of reference human genome. A 
higher reliability of annotation was achieved by the use of multiple databases (e.g. 1000Genomes, 
ExAc), collecting large amounts of data from different sources. The immediateness of the approach 
was based on the creation of a variant sharing table, allowing the simultaneous analysis of all the 17 
exomes and the rapid prioritization according to IBD haplotypes. On this purpose, it’s important to 
note that the mapping of variants into IBD haplotypes was not simply a positional localization, but it 
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accounted also of the sharing of variants. For example, if an haplotype cluster in a defined locus was 
including two patients among the sequenced ones, a variant in that locus must have been shared by 
the same two patients, and only them, to be included in the haplotype. Therefore, the filtering 
according to IBD map was extremely efficient, even considering the relative high number of shared 
haplotypes. Indeed, from the total 30,217 rare or novel variants, 6,621 (22%) mapped in the total IBD 
haplotypes (IBDtot), and only 558 (2%) in the IBDsel ones. The latter class of IBD haplotypes was 
selected because shared by more than two families and by at least half of the patients within each 
pedigree, thus, according to the original hypothesis, they could carry susceptibility alleles with strong 
effect on disease liability. 
 
5.5 Functional enrichment analyses 
An overall inspection of rare and novel variants mapping in IBD haplotypes revealed that two main 
biological processes were affected: axon guidance and synaptic transmission. Interestingly, both of 
these functions are related to neurosystem, thus potentially relevant for psychiatric disorders. 
 In this and in the following steps, no a priori selection based on variant effect was performed, for a 
series or reasons here described. First, the prioritization according to IBD haplotypes had revealed 
that no specific classes of variants were particularly more shared in patients. Further, functional 
enrichment analyses showed that the preferential distribution of variants in axon guidance and 
synaptic transmission processes was not driven by LoF coding effects, indirectly implicating 
synonymous or non-coding alleles. The involvement of regulative sequences in SCZ and BPD have 
been repeatedly suggested (Ament et al., 2015; Ripke et al., 2014). This hypothesis would be also 
coherent with the complex nature of the disorders, accounting for the environmental contribution and 
the polygenic inheritance, that likely exclude extremely damaging protein alterations. Unfortunately, 
current knowledge of regulative sequences is still incomplete and, consequently, prediction tools for 
changes other than non-synonymous substitutions may be inaccurate. Therefore, for the individual 
examination of variants, functional annotation of genes was retained more important than single 
variant effect, together with the fact that each of the variant was extremely rare (MAF<1%) or novel. 
 
The pathway analysis, however, highlighted that functional annotations, described in the mostly used 
repositories like KEGG and Reactome, include a variety of categories, assembled with different 
criteria. These comprehend for example large biological processes, like synaptic transmission, or 
generic signaling cascades, active in several tissues and intervening in multiple cellular functions. 
Another limitation of this approach is that a consistent fraction of genes is not mapped in any 
category; as a proof, an annotation was generally available for only a half of the tested genes. 
For all these reasons, enrichment was tested for 5 previously established gene sets, assembled after 
reliable proteomic data, such as the PSD-95 group, or more specific annotation categories, such as 
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glutamatergic synapse. The sets were selected on the basis of previously reported assumptions of 
implication, deriving both from GWASs and exome studies (Fromer et al., 2014; G Kirov et al., 2012; 
Purcell et al., 2014). Four of these were found significantly enriched in genes affected by rare or novel 
variants, mapping both in any of the IBD haplotypes (IBDtot) or in those most shared by patients 
(IBDsel). The sets include the broad glutamatergic synapse and three categories involved in 
glutamatergic postsynaptic functions, particularly the ones ascribable to signalling mediated by NMDA 
receptors (NMDA receptor pathway, PSD-95 and ARC complexes). These evidence indicated the 
advantages of the gene-set approach, allowing the test of more narrow functional hypotheses. The 
lower number of analyzed categories, in addition, reduced the effect of multiple testing correction, 
increasing the possibility to detect significant outcomes. Finally, the precise definition of gene sets 
partially overcomes the limitation deriving from the incomplete annotations of functional categories. 
Thanks to these benefits, it was possible to demonstrate a significant enrichment in the same 
converging functions also for the IBDsel set of variants, as was initially suggested by the only nominal 
significance in the general analysis performed with DAVID. The fourth gene set, composed by 
voltage-gated calcium channels (VGCCs), however, still reached significance only in IBDtot genes. 
In the light of these results, also the axon guidance pathway was further inspected, to reveal that 
again IBDtot and IBDsel variants were not uniformly distributed, but were clustering in genes involved in 
NCAM signalling for neurite outgrowth, thus in the formation of axon projections. 
 
 
Noticeably, some of the major pathogenetic hypothesis for SCZ and BPD revolve around the 
glutamatergic synapse and the formation of neuron projections. SCZ and BPD are considered in 
general neurodevelopmental disorders, caused by defects in brain pre- and post-natal maturation 
(Rapoport et al., 2012). More in detail, alterations in dendritic spines have been multiply observed in 
post-mortem brains from SCZ patients, suggesting an impairment in synaptic plasticity (Moyer et al., 
2015). NMDA glutamate receptors are known to be primarily involved in this phenomenon, triggering 
signalling cascades leading both to synapse potentiation and dendritic remodelling (Hall et al., 2015). 
In this context, PSD-95 complex is a major regulator of NMDA activity, while ARC proteins are 
downstream effectors modulating cytoskeleton rearrangements for projection growth. The signalling 
cascades rely upon a Ca2+ influx induced by glutamate, trough both NMDA receptors and VGCCs. 
The current model for SCZ posits a hypofunction of NMDA receptors, leading to a reduced plasticity, 
possibly driving the positive symptoms and the cognitive deficits seen in psychiatric cases. For BPD, 
instead, it has been evidenced that agonists of NMDA receptors improve depressive states. As 
discussed in paragraph 1.4, the NMDA-based model is also substantiated by several lines of genetic 
evidence, that have repeatedly implicated postsynaptic processes of glutamatergic transmission 
(Fromer et al., 2014; G Kirov et al., 2012; Purcell et al., 2014; Ripke et al., 2014). Further studies on 
structural brain abnormalities have however indicated that, beyond NMDA-mediated mechanisms, 
neuron projection development in general may be undermined. Rat models have shown for example 
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that enlarged ventricles and reduced brain volume, some of the most consistently found defects in 
SCZ, are the consequence of impairments in neurite outgrowth (Q. Zhang, Yu, & Huang, 2016). 
Additionally, functional Magnetic Resonance Imaging (fMRI) has highlighted a reduced connectivity 
between hippocampus and pre-frontal cortex in patients (Schmitt et al., 2011); similar observations 
have been made, although to a more limited extent, in BPD cases (Wessa et al., 2014). The findings 
presented in this work are consistent with what reported, sustaining a role for neurite formation in 
SCZ/BPD etiology, involving in particular NCAM signalling in axon guidance and NMDA postsynaptic 
functions for spine plasticity. These hypotheses have been originally advanced by studies on 
common risk factors (Ripke et al., 2014), then supported by investigations of rare sequencing variants 
(Fromer et al., 2014; Purcell et al., 2014). Therefore, the here described WES data further 
substantiate a broad convergence between common and rare variation at a functional level. 
 
5.6 Detailed investigation of variants in families 
Functional enrichment analyses are useful to understand which biological processes may be 
selectively affected by sets of variants. However, these strategies offer only global perspectives and 
ignore the actual occurrence of variants within the patients. To address this issue, the sharing of 
functionally relevant variants was inferred in the entire population, starting from the data of the 17 
exomes and exploiting the IBD map. 
An initial family-based investigation revealed a load of functionally related variants in pedigrees, 
suggesting a polygenic contribution to the disorders. This polygenic load was further in depth 
examined by the investigation of sharing and segregation of variants within and across families and 
some good candidate genes for SCZ/BPD emerged. 
CACNA1E encodes for an α1 subunit of VGCCs, whose role in pathogenesis has been repeatedly 
proposed (Purcell et al., 2014; Ripke et al., 2014), as already described. α1 subunits constitute the 
transmembrane pore, thus determine the conductance properties of these calcium channels; α1E 
characterizes CaV2.3 channels, activated by strong membrane depolarization in neurons and involved 
in neurotransmission. In particular, they have been shown to mediate presynaptic glutamate release 
(Heyes et al., 2015). Dysfunctions in CaV2.3 channels could thus cause alterations of the calcium 
current in the glutamatergic synapse, affecting both glutamate presence in the synaptic cleft and the 
Ca2+-triggered synaptic plasticity. In family 111, a synonymous CACNA1E variant was found together 
with an intronic FNBP1L (formin binding protein 1-like) one; the latter gene plays a major role in 
signalling cascades leading to actin cytoskeleton polymerization, necessary also for neuron projection 
and, again, plasticity. Interestingly, both variants are predicted to potentially cause alterations in 
splicing process. On the same line, FNBP1L allele perfectly co-segregates with SCZ in family 15, 
together with a variant in the DLG4 (disc large homolg 4 protein) gene, also known as PSD-95 (post 
synaptic density protein 95). DLG4 is a scaffolding protein of the posynaptic density, that is part of the 
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PSD-95 complex. It directly interacts with NMDA receptors, regulating their assembly and modulating 
downstream signal transduction. More in details, DLG4 binding to NMDA subunits has been shown to 
suppress dendritic branching, leading to the reduced plasticity typical of mature synapses (Bustos et 
al., 2014). The DLG4 gene has been indirectly associated with SCZ in gene-set studies on PSD-95 
complex (Fromer et al., 2014; Purcell et al., 2014). Even more, in the present work, two different 
variants, the first (described for family 111 and 15), synonymous and the latter in 5’ UTR region, were 
detected in this gene, mapping in different IBD haplotypes, shared by distinct group of families. Both 
of them again were predicted to affect splicing. This evidence further support the involvement of 
DLG4 in conferring risk for SCZ/BPD, in concomitance with other genes involved in plasticity, such as 
FNBP1L.  
Still in the context of glutamatergic hypothesis, GRM7 and GRM8 are type III metabotropic glutamate 
receptors, which regulate glutamate secretion and neuron excitability (Li et al., 2015). Both genes 
have been significantly associated with SCZ (Jajodia et al., 2015; Li et al., 2015; Ohtsuki et al., 2008) 
and BPD (Kandaswamy et al, 2014) in candidate-based studies. Additionally, a recent work in Han 
Chinese cohort not only did confirm the association, but proposed an interactive effect of variants in 
these two genes in conferring risk to SCZ (Li et al., 2015). Similarly, two synonymous rare alleles with 
damaging effects in GRM7 and GRM8 were found co-segregating in family 62. Interestingly, mouse 
models with GRM7 deficiency show behavioural phenotypes, ascribable to increased anxiety and 
depression, suggesting an implication of type III metabotropic glutamate receptors in psychiatric 
disorders (Li et al., 2015).  
 
Two more genes are especially of interest as found mutated in the same family and expressly 
involved in axon guidance: NCAM1 (neural cell adhesion molecule-1) and NCAN (neurocan). NCAM1 
variant is an intronic insertion that likely determines splice site changes; NCAN instead carries a LoF 
missense substitution. As mentioned before, NCAM1 is a key factor intervening in neurite outgrowth; 
as a transmembrane protein, it acts both as a cell adhesion and signalling molecule. The binding of 
neurocan, an extracellular matrix glycoprotein, inhibits adhesion and neurite formation (Retzler, 
Göhring, & Rauch, 1996). Remarkably, NCAN maps in one of the 108 genome-wide significant loci 
for SCZ and has been consistently associated also with BPD (Cichon et al., 2011; Ripke et al., 2014). 
Conversely, genetic lines of evidence have been so far inconclusive for NCAM1 association with 
SCZ/BPD; however, the here presented data suggest that the simultaneous occurrence of variants in 
NCAN and NCAM1 could increase risk for the disorders. 
Finally, the ARHGAP32 (Rho GTPase activating protein 32) and CDH13 (cadherin 13) genes 
emerged because carrying variants whose combination was detected in 5 patients across two 
different families. Again, these gene have related functions in neuronal development and the neurite 
formation. ARHGAP32 directly interacts with NMDA receptors, mediating actin polymerization for 
dendritic remodelling (Wayman et al., 2008). It has been demonstrated to promote axon growth 
during development (Kannan, Lee, Schwedhelm-Domeyer, Nakazawa, & Stegmüller, 2012). Similarly, 
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cadherin 13 is a cell adhesion molecule largely expressed in the brain and a negative regulator of 
neurite outgrowth, promoting synapse formation. Interestingly, CHD13 has been consistently 
associated with attention deficit- hyperactivity disorder (ADHD), another neuropsychiatric disorder 
that is thought to share part of etiology with SCZ and BPD (Rivero et al., 2013). 
As a last remark, other possible combinations analogous to ARHGAP32/CDH13 were identified, 
although they displayed a more limited sharing. One of these involved the SEMA3C (semaphoring 
3C) and CNTN2 (contactin 2), two genes of the axon guidance pathway. Another combination was 
found between the previously cited VGCC CACNA1E and a Ca2+ dependent kinase, PRKCB. These 
results could point to a possible interplay of alleles substantially increasing risk for SCZ/BPD. 
 
The overall scenario for the genetic architecture of SCZ and BPD, emerging from this study, is a 
complex puzzle of loci mapping on several chromosomes, each with a proper sharing pattern across 
the families. Some of these looked more broadly shared, encompassing multiple pedigrees, some 
other tended to be more private. This could be the case for variants in VGCCs other than CACNA1E, 
that usually were restricted to a single family; the observation is further supported by the outcome of 
the gene-set analysis, where the VGCC category was no more significant for IBDsel genes, selected 
because largely shared by patients. 
 
5.7 Strengths and limits of the study 
Exploiting the possibility to check the sharing and the segregation of variants in pedigrees, the 
reported study represents the first attempt to implicate specific alleles with SCZ and BPD. The work 
thus offers an example of the potential of family-based samples in the search of rare variants, in 
contraposition with case-control cohorts, that have so far restricted the investigations at pathway or 
gene-set level. Further, the homogeneity of the population sample was favourable for the 
identification of rare variants: alleles with a worldwide frequency <1% were instead multiply detected 
in the sample, increasing the possibility to track risk factors. Even in this simplified complexity, 
however, the polygenic nature of the disorders emerged, indicating that classical approaches 
developed for Mendelian traits are more likely to be unsuccessful. Beside the inter-familial 
heterogeneity, in fact, also intra-familial genetic diversity was observed, as initially hypothesized. 
Candidate risk variants were actually sometimes not common to all the patients of a family (e.g. 
FNBP1L in family 111), or showing an incomplete penetrance (e.g. CACNA1E in family 9). In this 
context, IBD mapping proved to be effective in tracking shared loci not only across different pedigrees 
but also within single pedigrees, where linkage approach has a reduced power given the small family 
extension. 
The sample features could also uncover some combinations of functionally related alleles that may 
consistently contribute to risk for SCZ/BPD. Interestingly, the analyzed population controls seemed 
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not only to display a lower load of such alleles, but also to carry none of the identified combinations. 
These observation can’t be however generalized or retained conclusive, considering the small 
number of control subjects available. 
Nevertheless, these outcomes looked particularly interesting, since they could be extremely useful for 
the identification of specific mechanisms for SCZ/BPD vulnerability. More precise pathogenetic 
hypotheses could be in fact more easily addressed also in model organisms for SCZ/BPD, such as 
rodents. If, on one hand, animal models can be extremely valuable for the study of pathogenesis, on 
the other hand phenotype evaluation in psychiatric disorders has always been a debated issue. 
Symptoms are indeed mostly behavioural, thus difficult to assess, and only molecular or biophysical 
alterations could be objectively investigated (Logan & McClung, 2015). In addition, the mutations that 
are induced in these models are in general extremely damaging, such as a complete knockout 
(O’Tuathaigh & Waddington, 2015). These type of variants are not coherent with what is currently 
known about the genetic architecture of SCZ and BPD, specifically with their polygenic nature. On the 
other hand, the simple presence of a single candidate variant would likely have no effect, for the 
same reasons. A major improvement could thus be achieved by the simultaneous test of multiple 
variants, especially those combinations that are more likely to substantially increase risk. 
 
 
Despite the cited advantages, this work presents some limitations. First, the search of risk factors was 
focused only on functionally relevant genes, as determined by the initial enrichment analysis. 
Although the investigated processes were not a priori determined, but indicted by the enrichment 
analysis itself, some biases could have been introduced as a consequence of incomplete 
annotations, as previously discussed. To improve this preliminary investigations, a more refined 
approach is currently under evaluation. This method, developed by professor Bortoluzzi’s team, 
implies the use of meta-networks, derived from annotated pathways, to unveil additional connections 
among genes (unpublished data). An example of a possible outcome is displayed in figure 5.1. The 
shown meta-network was obtained by the joint analysis of IBDsel and LoF IBDtot variants and 
highlighted a total of 87 genes, connected by relationships previously hidden. This would thus provide 
an improved functional prioritization of variants. 
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Figure 5.1: Pathway-derived network from genes affected by IBDsel and/or LoF variants. The results unveil connections 
between genes that were not evident in simply annotated pathways. 
 
A second limitation of the study is related to the main focus on coding sequences, a reflection of WES 
technique. Several lines of evidence have in fact sustained an important role for con-coding variation 
in SCZ and BPD. For example, in only 10 of the 108 loci associated with SCZ, the signal could be 
credibly attributable to an exonic, non-synonymous allele (Ripke et al., 2014). On the opposite, the 
same 108 loci were enriched in enhancers active in brain tissues. Similarly, in an exome study of 
bipolar families, 88% of variants within candidate pathways were located in non-coding regions 
(Ament et al., 2015). Also in the here presented work, about 50% of the prioritized variants, both in 
IBDsel and IBDtot categories, were located outside coding exons. These type of variants are generally 
excluded from analyses since their interpretation is complicated. The variants detected in this 
analysis, however, were all extremely rare or novel and, as described above, in functionally relevant 
genes. In addition, the high percentage of intronic variants was unlikely due to a simple bias from 
frequency annotations in databases, since several resources of different type, and collected with 
different technologies, were considered. Moreover, false positive calls were likely removed by filtering 
steps, particularly the mapping into IBD haplotypes, that requires a specific sharing of an allele in the 
sample, improbable to randomly occur. The low prediction abilities on the impact of these variants 
remain still a main limitation, that needs improvements, especially if a more thorough investigation of 
non-coding variants is envisioned, through whole-genome sequencing (WGS). The main issues when 
extending the analysis to the entire genome is, in fact, the interpretation and then the prioritization of 
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the huge amount of obtained variants. In this regards, IBD map would offer an effective strategy, 
again allowing the selection of variants according to a desired sharing. An explicative example 
emerged with the examination of co-segregating haplotypes. Together with CNTN2 and SEMA3C 
alleles, described above, a third locus on a different chromosome was shared with the same pattern, 
but no rare or novel variant was detected. Interestingly, the haplotype encompasses the CACNB4 
gene, encoding for a subunit of VGCCs. Both CNTN2 and VGCCs interact with NCAM1 for neurite 
formation; in particular, the binding with VGCCs determines a NCAM1-dependent Ca2+ influx that 
triggers several processes promoting the growth of active cones ( ref provided by Reactome manual 
annotation). It would be thus intriguing to assess whether some regulative variant outside exomic 
targets is actually located in this region. 
A final aspect that was not deeply explored is the possibility that some of the risk alleles was more 
specific for either SCZ or BPD. Beside the consistent overlap, in fact, genetic studies have shown that 
some characteristic variant must exist, driving the final phenotype towards one of the disorders 
(Craddock et al., 2009). Indeed, some preliminary observations identified variants shared only by 
SCZ patients (e.g. ARHGAP32). Again IBD map is a valuable tool for this purpose, since for any 
genomic locus is a priori possible to establish whether there is a preferential sharing in a specific 
class of phenotypes. Future investigations will thus provide further insights. 
5.8 Conclusions 
Concluding, this work provided an important contribution in understanding the genetic architecture of 
two SCZ and BPD. Firstly, it described a novel approach to investigate family-based samples with a 
common ancestry, relying on the construction of an IBD map. This map represents a flexible tool to 
address specific questions relative to candidate risk factors, thus allowing the testing of specific 
hypothesis, such as the existence of haplotype combinations or of phenotype-distinct loci. Moreover, 
the map can be used to prioritize variants from next-generation sequencing data, such as WES or, in 
the near future, WGS. Secondly, thanks to the integration of IBD and WES approaches, some 
insights on SCZ/BPD etiology were obtained. More in details, specific processes related to 
neurosystem development and functions were implicated and some candidate variants were 
provided, therefore substantiating the role of rare variation in susceptibility. Further insights will be 
necessary to establish the actual contribution of these rare variants in etiology. The whole picture is in 
fact far more complex, likely involving also common variants and environmental effects. 
Finally, considering the unique characteristics of the studied population, it’s difficult to predict whether 
the same alleles could be detected in independent samples. Nevertheless, in the light also of the 
general convergence of all types of genetic studies, the results could suggest possible genes or 
nodes of pathways that increase vulnerability to these psychiatric disorders. Further replications in 
other studies would thus support their involvement, ultimately suggesting new therapeutic targets for 
these common disorders that cause such a high burden for the society. 
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7. Appendix 
7.1 The 108 loci significantly associated with SCZ (Ripke et al., 2014) 
Rank P-value Position (hg19) SCZ† BPD† Protein coding genes 
1 3.48e-31 chr6:28303247-28712247 Y N Locus too broad 
2 3.362e-19 chr1:97792625-98559084 Y N DPYD MIR137 (micro-RNA) 
3 6.198e-19 
chr10:104423800-
105165583 
Y N 
ARL3 AS3MT C10orf32 CNNM2 CYP17A1 INA NT5C2 PCGF6 
PDCD11 SFXN2 TAF5 TRIM8 USMG5 WBP1L 
4 3.217e-18 chr12:2321860-2523731 Y Y CACNA1C 
5 1.737e-15 chr8:143309503-143330533 Y N TSNARE1 
6 7.98e-15 chr4:103146888-103198090 N N SLC39A8 
7 8.2e-15 chr7:1896096-2190096 Y N MAD1L1 
8 1.099e-14 chr5:60499143-60843543 Y N ZSWIM6 
9 1.859e-14 
chr12:123448113-
123909113 
Y N 
ABCB9 ARL6IP4 C12orf65 CDK2AP1 MPHOSPH9 OGFOD2 
PITPNM2 RILPL2 SBNO1 SETD8 
10 5.652e-14 chr2:200715237-200848037 Y N AC073043.2 C2orf47 C2orf69 TYW5 
11 8.296e-14 chr15:91416560-91429040 N N FES FURIN MAN2A2 
12 1.053e-13 chr3:36843183-36945783 N Y TRANK1 
13 1.363e-13 
chr14:103996234-
104184834 
N N 
AL049840.1 APOPT1 BAG5 CKB KLC1 PPP1R13B TRMT61A 
XRCC3 ZFYVE21 
14 2.439e-13 chr15:78803032-78926732 N N AC027228.1 AGPHD1 CHRNA3 CHRNA5 CHRNB4 IREB2 PSMA4 
15 3.034e-13 chr7:110843815-111205915 N N IMMP2L 
16 1.088e-12 
chr11:130714610-
130749330 
Y N SNX19 
17 1.53e-12 chr2:185601420-185785420 Y N ZNF804A 
18 1.606e-12 chrX:21193266-21570266 N N CNKSR2 
19 1.971e-12 chr10:18681005-18770105 Y N CACNB2 
20 2.015e-12 chr12:57428314-57682971 N N 
LRP1 MYO1A NAB2 NDUFA4L2 NXPH4 R3HDM2 SHMT2 STAC3 
STAT6 TAC3 TMEM194A 
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21 2.025e-12 chr1:73766426-73991366 Y N LRRIQ3 * 
22 2.315e-12 chr2:233559301-233753501 Y N C2orf82 EFHD1 GIGYF2 KCNJ13 NGEF 
23 2.804e-12 
chr11:124610007-
124620147 
Y N ESAM MSANTD2 NRGN VSIG2 
24 3.337e-12 chr18:52747686-53200117 Y N TCF4 
25 1.259e-11 chr11:46342943-46751213 Y N 
AMBRA1 ARHGAP1 ATG13 CHRM4 CKAP5 CREB3L1 DGKZ F2 
HARBI1 MDK ZNF408 
26 1.301e-11 chr3:180588843-181205585 N N CCDC39 DNAJC19 FXR1 
27 1.462e-11 chr20:37361494-37485994 N N ACTR5 PPP1R16B SLC32A1 
28 1.473e-11 chr2:57943593-58502192 Y N FANCL VRK2 
29 1.618e-11 chr15:84661161-85153461 N N ADAMTSL3 GOLGA6L4 ZSCAN2 
30 1.971e-11 chr18:53453389-53804154 N N TCF4 * 
31 2.064e-11 chr2:198148577-198835577 N N 
ANKRD44 BOLL COQ10B HSPD1 HSPE1 MARS2 PLCL1 RFTN2 
SF3B1 
32 2.069e-11 chr22:41408556-41675156 N N CHADL EP300 L3MBTL2 RANGAP1 
33 2.607e-11 chr8:111460061-111630761 N N KCNV1 * 
34 2.692e-11 chr3:2532786-2561686 N N CNTN4 
35 2.749e-11 
chr11:113317794-
113423994 
N N DRD2 
36 3.874e-11 
chr11:133808069-
133852969 
N N IGSF9B 
37 4.264e-11 chr3:52541105-52903405 Y N GLT8D1 GNL3 ITIH1 ITIH3 
38 4.548e-11 chr16:29924377-30144877 N N 
ALDOA ASPHD1 C16orf92 DOC2A FAM57B GDPD3 HIRIP3 
INO80E KCTD13 MAPK3 PPP4C SEZ6L2 TAOK2 TBX6 TMEM219 
YPEL3 
39 4.725e-11 chr22:39975317-40016817 N N CACNA1I 
40 7.264e-11 chr3:135807405-136615405 N N MSL2 NCK1 PCCB PPP2R3A SLC35G2 STAG1 
41 1.055e-10 chr5:151941104-152797656 Y N GRIA1 * 
42 1.982e-10 chrX:68377126-68379036 N N PJA1 
43 2.862e-10 chr17:2095899-2220799 N N SGSM2 SMG6 SRR TSR1 
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44 3.332e-10 chr7:86403226-86459326 N N GRM3 
45 3.384e-10 chr15:61831663-61909663 N N VPS14C * 
46 3.394e-10 chr1:44029384-44128084 N N KDM4A PTPRF 
47 3.634e-10 chr19:19374022-19658022 Y Y 
CILP2 GATAD2A HAPLN4 MAU2 NCAN NDUFA13 PBX4 SUGP1 
TM6SF2 TSSK6 
48 4.487e-10 chr1:149998890-150242490 N N ANP32E APH1A C1orf51 C1orf54 CA14 OTUD7B PLEKHO1 VPS45 
49 8.147e-10 chr6:84279922-84407274 N N SNAP91 
50 8.701e-10 chr1:2372401-2402501 N N PLCH2 
51 1.009e-9 chr16:13728459-13761359 N N ERCC4 * 
52 1.127e-9 chr7:104598064-105063064 N N MLL5 PUS7 SRPK2 
53 1.166e-9 chr1:8411184-8638984 N N RERE SLC45A1 
54 1.398e-9 
chr12:110723245-
110723245 
N N ATP2A2 
55 1.465e-9 chr4:170357552-170646052 N N C4orf27 CLCN3 NEK1 
56 1.644e-9 chr6:96459651-96459651 N N FUT9 
57 1.709e-9 chr22:42315744-42689414 N N 
CENPM CYP2D6 FAM109B NAGA NDUFA6 SEPT3 SHISA8 
SMDT1 SREBF2 TCF20 TNFRSF13C WBP2NL 
58 1.814e-9 chr2:146416922-146441832 N N 
 
59 2.243e-9 chr11:57386294-57682294 N N 
BTBD18 C11orf31 CLP1 CTNND1 MED19 SERPING1 TMX2 YPEL4 
ZDHHC5 
60 2.554e-9 chr11:24367320-24412990 N N LUZP2 * 
61 2.86e-9 chr1:30412551-30437271 N N 
 
62 3.278e-9 chr7:137039644-137085244 N N DGKI PTN 
63 3.613e-9 chr9:84630941-84813641 N N TLE1 
64 3.73e-9 chr1:243503719-244002945 Y N AKT3 SDCCAG8 
65 4.178e-9 chr15:40566759-40602237 N N ANKRD63 PAK6 PLCB2 
66 4.489e-9 chr19:30981643-31039023 N N ZNF536 
67 4.606e-9 chr5:88581331-88854331 N N MEF2C * 
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68 4.642e-9 chr3:17221366-17888266 N N TBC1D5 
69 4.666e-9 chr5:137598121-137948092 N N 
CDC25C CTNNA1 EGR1 ETF1 FAM53C GFRA3 HSPA9 KDM3B 
REEP2 
70 4.801e-9 chr14:99707919-99719219 N N BCL11B 
71 4.863e-9 chr14:72417326-72450526 N N AC005477.1 RGS6 
72 5.046e-9 chr5:45291475-45393775 N N HCN1 
73 5.97e-9 chr8:60475469-60954469 N N CA8 * 
74 7.388e-9 chr2:72357335-72368185 N N CYP26B1 
75 7.539e-9 
chr11:123394636-
123395986 
N N GRAMD1B 
76 8.333e-9 chr2:200161422-200309252 N N SATB2 
77 8.408e-9 chr2:193848340-194028340 Y N PCGEM1 * 
78 9.469e-9 chr4:176851001-176875801 N N GPM6A 
79 1.058e-8 chr8:4177794-4192544 Y N CSMD1 
80 1.115e-8 chr2:225334096-225467796 N N CUL3 
81 1.215e-8 chr8:89340626-89753626 Y N MMP16 
82 1.28e-8 chr16:9875519-9970219 N N GRIN2A 
83 1.411e-8 chr14:30189985-30190316 N N PRKD1 
84 1.432e-8 chr3:63792650-64004050 N N ATXN7 C3orf49 PSMD6 THOC7 
85 1.513e-8 chr16:67709340-68311340 N N 
ACD C16orf86 CENPT CTRL DDX28 DPEP2 DPEP3 DUS2L EDC4 
ENKD1 ESRP2 GFOD2 LCAT NFATC3 NRN1L NUTF2 PARD6A 
PLA2G15 PSKH1 PSMB10 RANBP10 SLC12A4 SLC7A6 
SLC7A6OS THAP11 TSNAXIP1 
86 1.585e-8 chr2:149390778-149520178 N N EPC2 
87 1.769e-8 chr17:17722402-18030202 N N ATPAF2 DRG2 GID4 LRRC48 MYO15A RAI1 SREBF1 TOM1L2 
88 1.787e-8 chr15:70573672-70628872 N N TLE3 * 
89 1.873e-8 chr16:58669293-58682833 N N CNOT1 SLC38A7 
90 2.096e-8 chr8:27412627-27453627 N N CLU EPHX2 
91 2.205e-8 chrX:5916533-6032733 N N NLGN4X 
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92 2.688e-8 chr6:73132701-73171901 N N RIMS1 
93 2.853e-8 chr7:24619494-24832094 N N DFNA5 MPP6 OSBPL3 
94 3.053e-8 chr5:109030036-109209066 N N MAN2A1 
95 3.056e-8 chr4:23366403-23443403 N N MIR548AJ2 * 
96 3.145e-8 chr5:153671057-153688217 N N GALNT10 
97 3.695e-8 
chr11:109285471-
109610071 
N N C11orf87 
98 3.713e-8 chr7:110034393-110106693 N N IMMP2L * 
99 3.906e-8 chr12:29905265-29940365 N N TMTC1 
100 4.417e-8 chr7:131539263-131567263 N N PODXL * 
101 4.448e-8 chr1:177247821-177300821 N N FAM5B 
102 4.468e-8 chr1:207912183-208024083 N N C1orf132 CD46 CR1L 
103 4.559e-8 chr20:48114136-48131649 N N KCNB1 PTGIS 
104 4.591e-8 chr12:92243186-92258286 N N C12orf79 * 
105 4.615e-8 chr2:162798555-162910255 N N DPP4 SLC4A10 
106 4.686e-8 chr19:50067499-50135399 N N NOSIP PRR12 PRRG2 RCN3 RRAS SCAF1 
107 4.843e-8 
chr12:103559855-
103616655 
N N C12orf42 
108 4.849e-8 chr5:140023664-140222664 N N 
AC005609.1 CD14 DND1 HARS HARS2 IK NDUFA2 PCDHA1 
PCDHA10 PCDHA2 PCDHA3 PCDHA4 PCDHA5 PCDHA6 PCDHA7 
PCDHA8 PCDHA9 TMCO6 WDR55 ZMAT2 
† indicates whether the locus has been previously reported with SCZ (schizophrenia) or BPD (bipolar 
disorder) 
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7.2 The 10 loci significantly associated with BPD 
Locus P-value Genes Reference 
12p13.3 1.5e-8 CACNA1C (Ferreira et al., 2008) 
10q21.2 9.1e-9 ANK3 (Ferreira et al., 2008) 
11q14.1 4.4e-8 ODZ4 (Sklar et al., 2011) 
19p13.1 2.1e-9 NCAN (Cichon et al., 2011) 
3p22.2 2.4e-11 TRANK1 (Chen et al., 2013) 
6q25.1 2.9e-8 SYNE1 (Green et al., 2013a) 
12q13.1 9.0e-9 RHEBL1 DHH (Green et al., 2013b) 
20q11.2 3.9e-8 TRPC4AP GSS MYH7B (Green et al., 2013b) 
5p15.3 9.9e-9 ADCY2 (Mühleisen et al., 2014) 
6q16.1 1.1e-8 MIR2113 POU3F2 (Mühleisen et al., 2014) 
 
7.3 List of local origins (Chioggia or Sottomarina) for the 115 ‘family 
founders’ 
Ind Family Reported origin Revised origin Outsider Sample type 
1_1 1 C C N familial 
1_2 1 C C N familial 
1_3 1 C C N familial 
2_4 2 C C N familial 
3_1 3 C C N familial 
4_11 4a S C Y familial 
4_2 4 S S N familial 
4_4 4 S S N familial 
5_3 5 S S N familial 
6_1 6 S C N familial_single 
7_1 7 C C N familial 
8_1 8 C C N familial 
9_1 9 C C N familial 
11_1 11 C C N familial 
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13_1 13 S C Y familial 
14_2 14 S C N familial_single 
15_2 15 S C N familial 
15_5 15 S C N familial 
16_1 16 S S N familial 
17_1 17 C C N familial_single 
19_1 19 S S N familial 
20_1 20 S S N familial 
20_2 20 S S N familial 
21_1 21 C S N familial 
22_1 22 C C N familial 
22_6 22 C C N familial 
23_2 23 C C N familial 
24_1 24 C C N familial 
26_1 26 S C N familial 
26_3 26 S C N familial 
26_6 26 S C N familial 
27_1 27 C C N familial 
28_1 28 S C N familial_single 
34_1 34 S C Y familial_single 
34_2 34 S S N familial_single 
40_1 40 S S N familial 
44_1 44 C C Y familial_single 
45_1 45 S S N familial_single 
47_1 47 C C N familial 
48_1 48 C C N familial 
48_4 48 C C N familial 
53_1 53 ND C N familial_single 
54_1 54 ND C N familial_single 
55_1 55 ND C Y familial_single 
56_1 56 S C N familial_single 
62_1 62 S S N familial 
62_4 62 S S N familial_single 
63_1 63 ND C N familial_single 
64_1 64 ND C N familial_single 
69_1 69 S S N familial_single 
78_1 78 ND C N familial 
79_2 79 S S N familial 
79_5 79 S S N familial 
80_1 80 S S N familial 
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84_1 84 S S N familial 
85_1 85 S S N familial 
86_1 86 ND C N familial_single 
87_1 87 ND C Y familial_single 
88_1 88 ND C N familial_single 
90_2 90 C C N familial_single 
91_1 91 ND C Y familial_single 
97_1 97 S S N familial_single 
99_3 99 C C N familial 
100_1 100 ND C N familial_single 
103_1 103 S S N familial_single 
109_1 109 C C N familial 
109_2 109 C C N familial_single 
110_1 110 C C N familial 
111_1 111 C C N familial 
115_3 115 ND C N familial 
29 29 C C N isolated 
30 30 S S N isolated 
31 31 S S N isolated 
32 32 C C N isolated 
35 35 S C N isolated 
36 36 S S N isolated 
37 37 C C N isolated 
38 38 S C N isolated 
39 39 C C N isolated 
41 41 C C N isolated 
42 42 C C N isolated 
50 50 ND C N isolated 
51 51 S S N isolated 
52 52 C C N isolated 
57 57 S S N isolated 
58 58 ND C N isolated 
59 59 ND C N isolated 
60 60 C C N isolated 
61 61 ND C N isolated 
67 67 ND C N isolated 
68 68 ND C N isolated 
70 70 ND C Y isolated 
71 71 ND C Y isolated 
72 72 ND C Y isolated 
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73 73 ND C Y isolated 
74 74 ND C Y isolated 
75 75 C C N isolated 
76 76 S C N isolated 
96 96 ND C N isolated 
101 101 C C N isolated 
104 104 S C N isolated 
c6484 c6484 S S N control 
c6485 c6485 S S N control 
c7791 c7791 S S N control 
c7863 c7863 S C Y control 
c7995 c7995 S S N control 
c7996 c7996 C C N control 
c7998 c7998 S S N control 
c8002 c8002 S S N control 
c8008 c8008 S S N control 
c8018 c8018 C C N control 
c8019 c8019 S S N control 
c8047 c8047 S S N control 
c8049 c8049 C C N control 
c8050 c8050 C C N control 
For each individual is reported the initially reported origin and the revised one in the light of cluster analysis. The outsider 
column indicate whether the subject was grouped in the Italian cluster outside Chioggia population. 
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7.4 Detailed results of the functional enrichment analysis 
all rare or novel variants 
Category Term 
Matched 
genes % PValue 
Tot genes 
tested 
Tot genes in 
the category Benjamini 
KEGG_PATHWAY hsa04510:Focal adhesion 153 1.384615 1.24E-05 3133 201 0.00246025 
KEGG_PATHWAY 
hsa04512:ECM-receptor 
interaction 70 0.633484 3.42E-05 3133 84 0.00339728 
KEGG_PATHWAY 
hsa00500:Starch and 
sucrose metabolism 38 0.343891 1.38E-04 3133 42 0.00909936 
KEGG_PATHWAY 
hsa00230:Purine 
metabolism 116 1.049774 2.22E-04 3133 153 0.01100489 
KEGG_PATHWAY 
hsa04070:Phosphatidylinosi
tol signaling system 61 0.552036 2.31E-04 3133 74 0.00913323 
KEGG_PATHWAY 
hsa04520:Adherens 
junction 63 0.570136 2.65E-04 3133 77 0.00874236 
REACTOME_PATHW
AY 
REACT_13685:Synaptic 
Transmission 65 0.588235 2.93E-04 2061 81 0.02059656 
REACTOME_PATHW
AY 
REACT_11044:Signaling by 
Rho GTPases 93 0.841629 5.48E-04 2061 123 0.0192842 
KEGG_PATHWAY hsa04360:Axon guidance 98 0.886878 6.68E-04 3133 129 0.01881109 
KEGG_PATHWAY hsa02010:ABC transporters 38 0.343891 
0.001025
2 3133 44 0.02519145 
REACTOME_PATHW
AY 
REACT_18266:Axon 
guidance 41 0.371041 
0.001298
7 2061 49 0.03028768 
REACTOME_PATHW
AY 
REACT_16888:Signaling by 
PDGF 51 0.461538 
0.002149
7 2061 64 0.03747722 
KEGG_PATHWAY 
hsa00562:Inositol 
phosphate metabolism 44 0.39819 
0.003524
7 3133 54 0.07510288 
KEGG_PATHWAY 
hsa04930:Type II diabetes 
mellitus 39 0.352941 
0.003681
3 3133 47 0.07076393 
KEGG_PATHWAY 
hsa05412:Arrhythmogenic 
right ventricular 
cardiomyopathy (ARVC) 59 0.533937 
0.004528
8 3133 76 0.07883426 
REACTOME_PATHW
AY 
REACT_11061:Signalling by 
NGF 124 1.122172 
0.005584
7 2061 176 0.07644444 
KEGG_PATHWAY hsa04144:Endocytosis 131 1.18552 
0.005659
9 3133 184 0.08983177 
REACTOME_PATHW
AY 
REACT_474:Metabolism of 
carbohydrates 70 0.633484 0.005945 2061 94 0.06812693 
REACTOME_PATHW
AY 
REACT_13552:Integrin cell 
surface interactions 61 0.552036 
0.007255
7 2061 81 0.07120022 
KEGG_PATHWAY 
hsa04270:Vascular smooth 
muscle contraction 82 0.742081 
0.010687
2 3133 112 0.15166258 
REACTOME_PATHW
AY REACT_216:DNA Repair 74 0.669683 
0.012910
7 2061 102 0.1089269 
REACTOME_PATHW
AY 
REACT_17044:Muscle 
contraction 26 0.235294 
0.014628
7 2061 31 0.10975318 
REACTOME_PATHW
AY 
REACT_602:Metabolism of 
lipids and lipoproteins 105 0.950226 
0.014904
5 2061 150 0.10113142 
KEGG_PATHWAY hsa05414:Dilated 68 0.615385 0.015198 3133 92 0.19562471 
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cardiomyopathy 2 
KEGG_PATHWAY 
hsa00053:Ascorbate and 
aldarate metabolism 16 0.144796 
0.016901
1 3133 17 0.20239126 
KEGG_PATHWAY 
hsa05410:Hypertrophic 
cardiomyopathy (HCM) 63 0.570136 
0.018184
7 3133 85 0.2040781 
KEGG_PATHWAY 
hsa05200:Pathways in 
cancer 221 2 
0.019428
5 3133 328 0.20520063 
KEGG_PATHWAY 
hsa04730:Long-term 
depression 52 0.470588 
0.021096
7 3133 69 0.21000687 
KEGG_PATHWAY 
hsa04330:Notch signaling 
pathway 37 0.334842 
0.021615
8 3133 47 0.20457542 
KEGG_PATHWAY 
hsa04720:Long-term 
potentiation 51 0.461538 
0.025858
3 3133 68 0.22946892 
KEGG_PATHWAY 
hsa04910:Insulin signaling 
pathway 95 0.859729 
0.030339
7 3133 135 0.2531993 
KEGG_PATHWAY 
hsa00410:beta-Alanine 
metabolism 19 0.171946 
0.036799
7 3133 22 0.28762365 
KEGG_PATHWAY 
hsa00640:Propanoate 
metabolism 26 0.235294 
0.036828
9 3133 32 0.27723133 
KEGG_PATHWAY 
hsa04650:Natural killer cell 
mediated cytotoxicity 93 0.841629 
0.040324
6 3133 133 0.28914493 
KEGG_PATHWAY 
hsa04912:GnRH signaling 
pathway 70 0.633484 
0.042222
4 3133 98 0.29064005 
KEGG_PATHWAY 
hsa00970:Aminoacyl-tRNA 
biosynthesis 32 0.289593 
0.042399
5 3133 41 0.2822253 
KEGG_PATHWAY 
hsa04666:Fc gamma R-
mediated phagocytosis 68 0.615385 
0.042769
2 3133 95 0.27542099 
KEGG_PATHWAY 
hsa00280:Valine, leucine 
and isoleucine degradation 34 0.307692 
0.043583
1 3133 44 0.27145386 
KEGG_PATHWAY 
hsa04010:MAPK signaling 
pathway 179 1.61991 0.044951 3133 267 0.27065205 
KEGG_PATHWAY hsa05416:Viral myocarditis 52 0.470588 
0.046062
6 3133 71 0.26861098 
REACTOME_PATHW
AY REACT_604:Hemostasis 156 1.411765 
0.047070
7 2061 235 0.26743479 
rare or novel IBDtot variants 
KEGG_PATHW
AY hsa04512:ECM-receptor interaction 44 
1.0096
37 
2.59E-
07 
128
8 84 
5.11E-
05 
REACTOME_P
ATHWAY REACT_11044:Signaling by Rho GTPases 51 
1.1702
62 
2.79E-
05 822 
12
3 
0.0018
9395 
KEGG_PATHW
AY hsa02010:ABC transporters 25 
0.5736
58 
3.06E-
05 
128
8 44 
0.0030
1196 
REACTOME_P
ATHWAY REACT_18266:Axon guidance 26 
0.5966
04 
3.82E-
05 822 49 
0.0012
9938 
KEGG_PATHW
AY hsa04510:Focal adhesion 74 
1.6980
27 
2.70E-
04 
128
8 
20
1 
0.0175
6438 
REACTOME_P
ATHWAY REACT_604:Hemostasis 76 
1.7439
19 
0.00315
97 822 
23
5 
0.0692
2081 
KEGG_PATHW
AY hsa00500:Starch and sucrose metabolism 20 
0.4589
26 
0.00383
43 
128
8 42 
0.1723
7915 
KEGG_PATHW
AY hsa04070:Phosphatidylinositol signaling system 30 
0.6883
89 
0.00564
49 
128
8 74 
0.1999
1724 
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REACTOME_P
ATHWAY REACT_13685:Synaptic Transmission 31 
0.7113
35 
0.00601
69 822 81 
0.0975
0913 
KEGG_PATHW
AY hsa04720:Long-term potentiation 28 
0.6424
97 
0.00605
44 
128
8 68 
0.1807
6905 
KEGG_PATHW
AY hsa05200:Pathways in cancer 103 
2.3634
69 
0.00851
23 
128
8 
32
8 
0.2138
3325 
KEGG_PATHW
AY 
hsa05412:Arrhythmogenic right ventricular cardiomyopathy 
(ARVC) 30 
0.6883
89 
0.00868
64 
128
8 76 
0.1933
2765 
REACTOME_P
ATHWAY REACT_13552:Integrin cell surface interactions 30 
0.6883
89 0.01164 822 81 
0.1472
0244 
KEGG_PATHW
AY hsa05410:Hypertrophic cardiomyopathy (HCM) 32 
0.7342
82 
0.01408
91 
128
8 85 
0.2669
8347 
KEGG_PATHW
AY hsa00052:Galactose metabolism 13 
0.2983
02 0.01681 
128
8 26 
0.2839
257 
REACTOME_P
ATHWAY REACT_16888:Signaling by PDGF 24 
0.5507
11 
0.02217
94 822 64 
0.2244
6053 
KEGG_PATHW
AY hsa00230:Purine metabolism 51 
1.1702
62 
0.02300
76 
128
8 
15
3 
0.3408
8678 
KEGG_PATHW
AY hsa00250:Alanine, aspartate and glutamate metabolism 14 
0.3212
48 
0.03133
58 
128
8 31 
0.4070
5961 
KEGG_PATHW
AY hsa00562:Inositol phosphate metabolism 21 
0.4818
72 
0.03689
2 
128
8 54 
0.4342
6501 
KEGG_PATHW
AY hsa04360:Axon guidance 43 
0.9866
91 
0.03721
99 
128
8 
12
9 
0.4135
881 
KEGG_PATHW
AY hsa00053:Ascorbate and aldarate metabolism 9 
0.2065
17 
0.04279
46 
128
8 17 
0.4369
6687 
KEGG_PATHW
AY hsa05414:Dilated cardiomyopathy 32 
0.7342
82 
0.04334
95 
128
8 92 
0.4205
3809 
KEGG_PATHW
AY hsa00982:Drug metabolism 23 
0.5277
65 
0.04741
49 
128
8 62 
0.4304
4974 
rare or novel IBDsel variants 
KEGG_PATHW
AY hsa04360:Axon guidance 10 
1.9455
25 
0.01635
44 156 
12
9 
0.8865
761 
KEGG_PATHW
AY hsa04070:Phosphatidylinositol signaling system 7 
1.3618
68 
0.02453
7 156 74 
0.8059
5067 
BIOCARTA h_blymphocytePathway:B Lymphocyte Cell Surface Molecules 3 
0.5836
58 
0.02471
83 34 11 
0.9095
3325 
REACTOME_P
ATHWAY REACT_18266:Axon guidance 5 
0.9727
63 
0.02598
58 80 49 
0.5914
7429 
REACTOME_P
ATHWAY REACT_15380:Diabetes pathways 13 
2.5291
83 
0.02991
83 80 
28
5 
0.4033
2075 
REACTOME_P
ATHWAY REACT_13685:Synaptic Transmission 6 
1.1673
15 
0.03875
71 80 81 
0.3610
8648 
KEGG_PATHW
AY hsa04514:Cell adhesion molecules (CAMs) 9 
1.7509
73 
0.04746
14 156 
13
2 
0.8822
8449 
all rare or novel LoF variants 
KEGG_PATHW
AY hsa02010:ABC transporters 30 
0.5735
04 
1.65E-
07 
142
4 44 
3.22E-
05 
KEGG_PATHW
AY hsa04512:ECM-receptor interaction 46 
0.8793
73 
5.68E-
07 
142
4 84 
5.54E-
05 
KEGG_PATHW
AY hsa05416:Viral myocarditis 34 
0.6499
71 
6.33E-
04 
142
4 71 
0.0403
4419 
95 
 
REACTOME_P
ATHWAY REACT_13552:Integrin cell surface interactions 36 
0.6882
05 
9.85E-
04 915 81 
0.0647
8796 
KEGG_PATHW
AY hsa04612:Antigen processing and presentation 36 
0.6882
05 
0.00358
31 
142
4 83 
0.1605
3626 
KEGG_PATHW
AY hsa00500:Starch and sucrose metabolism 21 
0.4014
53 
0.00513
58 
142
4 42 
0.1819
3541 
KEGG_PATHW
AY hsa04510:Focal adhesion 73 
1.3955
27 0.00822 
142
4 
20
1 
0.2352
8651 
KEGG_PATHW
AY hsa00563:Glycosylphosphatidylinositol(GPI)-anchor biosynthesis 14 
0.2676
35 
0.00935
8 
142
4 25 
0.2304
2331 
KEGG_PATHW
AY hsa00562:Inositol phosphate metabolism 24 
0.4588
03 
0.01447
98 
142
4 54 
0.2991
9485 
KEGG_PATHW
AY hsa00970:Aminoacyl-tRNA biosynthesis 19 
0.3632
19 
0.02063
59 
142
4 41 
0.3635
1192 
REACTOME_P
ATHWAY REACT_18266:Axon guidance 21 
0.4014
53 
0.02322
78 915 49 
0.5502
494 
KEGG_PATHW
AY hsa04070:Phosphatidylinositol signaling system 30 
0.5735
04 
0.02353
08 
142
4 74 
0.3714
4704 
KEGG_PATHW
AY hsa05332:Graft-versus-host disease 18 
0.3441
02 
0.02604
66 
142
4 39 
0.3736
5539 
REACTOME_P
ATHWAY REACT_649:Phase 1 functionalization 9 
0.1720
51 
0.02650
09 915 15 
0.4559
9121 
REACTOME_P
ATHWAY REACT_11044:Signaling by Rho GTPases 44 
0.8411
39 
0.02774
97 915 
12
3 
0.3802
3393 
KEGG_PATHW
AY hsa04514:Cell adhesion molecules (CAMs) 48 
0.9176
07 
0.03225
19 
142
4 
13
2 
0.4130
0087 
KEGG_PATHW
AY hsa04360:Axon guidance 46 
0.8793
73 
0.04972
74 
142
4 
12
9 
0.5347
1057 
rare or novel LoF IBDtot variants 
KEGG_PATHW
AY hsa04512:ECM-receptor interaction 18 
1.1235
96 
9.11E-
04 452 84 
0.1442
58 
KEGG_PATHW
AY hsa00830:Retinol metabolism 12 
0.7490
64 
0.00676
92 452 54 
0.4405
127 
KEGG_PATHW
AY hsa00982:Drug metabolism 13 
0.8114
86 
0.00730
35 452 62 
0.3415
2429 
REACTOME_P
ATHWAY REACT_11044:Signaling by Rho GTPases 19 
1.1860
17 
0.00780
09 272 
12
3 
0.3345
1467 
KEGG_PATHW
AY hsa00983:Drug metabolism 10 
0.6242
2 
0.01154
23 452 43 
0.3912
2371 
KEGG_PATHW
AY 
hsa05412:Arrhythmogenic right ventricular cardiomyopathy 
(ARVC) 14 
0.8739
08 
0.01509
83 452 76 
0.4056
5755 
KEGG_PATHW
AY hsa00860:Porphyrin and chlorophyll metabolism 8 
0.4993
76 
0.02311
69 452 33 
0.4865
3158 
REACTOME_P
ATHWAY REACT_649:Phase 1 functionalization 5 
0.3121
1 
0.02673
03 272 15 
0.5056
1722 
KEGG_PATHW
AY hsa00500:Starch and sucrose metabolism 9 
0.5617
98 
0.02882
77 452 42 
0.5105
9699 
REACTOME_P
ATHWAY REACT_18266:Axon guidance 9 
0.5617
98 
0.03769
47 272 49 
0.4862
4483 
KEGG_PATHW
AY hsa04640:Hematopoietic cell lineage 14 
0.8739
08 
0.03838
41 452 86 
0.5668
2807 
KEGG_PATHW
AY hsa04514:Cell adhesion molecules (CAMs) 19 
1.1860
17 
0.04219
65 452 
13
2 
0.5591
8904 
96 
 
7.5 Detailed information about the investigated variants 
type chr genomic position ref variant gene effect prediction 
rare 1 93964859 G A FNBP1L intronic damaging 
rare 1 181727109 C T CACNA1E synonymous damaging 
rare 1 205028229 C T CNTN2 missense damaging 
rare 3 7494298 G A GRM7 synonymous damaging 
new 3 173998947 A G NLGN1 missense damaging 
rare 7 80430250 G T SEMA3C intronic neutral 
new 7 126173624 G A GRM8 synonymous damaging 
new 8 38271545 C T FGFR1 intronic damaging 
new 11 113102000 G GGCT NCAM1 intronic neutral 
rare 11 128842742 C T ARHGAP32 missense neutral 
rare 16 24231449 C T PRKCB utr_3 damaging 
new 16 83520283 T C CDH13 intronic neutral 
rare 16 83712083 G A CDH13 intronic neutral 
rare 17 7096390 G A DLG5 synonymous damaging 
rare 17 7096390 G A DLG4 synonymous damaging 
new 17 7120502 T TCA DLG4 utr_5 damaging 
new 19 19356155 A C NCAN missense damaging 
 
7.6 Primer list for Sanger sequencing of candidate variants 
Primer Sequence 
DLG4a_F ACTTCTGATGCTGCCACTCC 
DLG4a_R CGAAATCCAGTTCCCCTCCC 
DLG4b_F AGGGGAGAAGGAAGAGGACC  
DLG4b_R GCTGGGCACTATGGGGATTT 
CACNA1E_F GCTAATAACCATGACTTTCT 
CACNA1E_R ATAAGATCACAAAAGGATTC 
PRKCB_F CAGAGAGACAAGAGAGACAC 
PRKCB_R CAGACACAGTAGTTTTGACA 
GRM7_F GTATGTAAGGTGTCACAAAG 
GRM7_R CAGAGATCCTTGTTCATG 
GRM8_F GATGCTGGACTAATGAACT 
GRM8_R GCTGTGAAGGTTACAACT 
CNTN2_F ACTTTCCATCGTTGTGCCCT 
CNTN2_R AGGAGTAGTTGCCCAGGTCT 
NCAM1_F GCAGACAGAAAGGACAGGCT 
NCAM1_R ATTGGTTTGGGGCTAGGTCC 
97 
 
NCAN_F CACCACTTATCTAACACTGA 
NCAN_R AGACATAGGGTAGGTTGTAG 
ARHGAP32_F TGGAGTAGTTGTCATGTAAG 
ARHGAP32_R TTACTTCAGTTCCCTTAGAC 
CDH13_F TTTCTGCCTTCCACACCCTG  
CDH13_R GTCAGCCACAACCTCCTCTC 
 
 
